<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents - Brigo, F - 2021 | Cochrane Library</title> <meta content="Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents - Brigo, F - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003032.pub5/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents - Brigo, F - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003032.pub5/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003032.pub5" name="dc.identifier" scheme="DOI"/> <meta content="Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents" name="citation_title"/> <meta content="Francesco Brigo" name="citation_author"/> <meta content="Hospital of Merano (SABES-ASDAA)" name="citation_author_institution"/> <meta content="dr.francescobrigo@gmail.com" name="citation_author_email"/> <meta content="Stanley C Igwe" name="citation_author"/> <meta content="Alex Ekwueme Federal University Teaching Hospital (AEFUTHA)" name="citation_author_institution"/> <meta content="Simona Lattanzi" name="citation_author"/> <meta content="Marche Polytechnic University" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD003032.pub5" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/01/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003032.pub5/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003032.pub5/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003032.pub5/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticonvulsants [adverse effects, *therapeutic use]; Epilepsy, Absence [*drug therapy, prevention &amp; control]; Ethosuximide [adverse effects, *therapeutic use]; Lamotrigine [adverse effects, *therapeutic use]; Randomized Controlled Trials as Topic; Seizures [prevention &amp; control]; Treatment Failure; Valproic Acid [adverse effects, *therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003032.pub5&amp;doi=10.1002/14651858.CD003032.pub5&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003032.pub5&amp;doi=10.1002/14651858.CD003032.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003032.pub5&amp;doi=10.1002/14651858.CD003032.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003032.pub5&amp;doi=10.1002/14651858.CD003032.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003032.pub5&amp;doi=10.1002/14651858.CD003032.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003032.pub5&amp;doi=10.1002/14651858.CD003032.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003032.pub5&amp;doi=10.1002/14651858.CD003032.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003032.pub5&amp;doi=10.1002/14651858.CD003032.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003032.pub5&amp;doi=10.1002/14651858.CD003032.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003032.pub5&amp;doi=10.1002/14651858.CD003032.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003032.pub5&amp;doi=10.1002/14651858.CD003032.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003032.pub5&amp;doi=10.1002/14651858.CD003032.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003032.pub5&amp;doi=10.1002/14651858.CD003032.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003032.pub5&amp;doi=10.1002/14651858.CD003032.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003032.pub5&amp;doi=10.1002/14651858.CD003032.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003032.pub5&amp;doi=10.1002/14651858.CD003032.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003032.pub5&amp;doi=10.1002/14651858.CD003032.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003032.pub5&amp;doi=10.1002/14651858.CD003032.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003032.pub5&amp;doi=10.1002/14651858.CD003032.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003032.pub5&amp;doi=10.1002/14651858.CD003032.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003032.pub5&amp;doi=10.1002/14651858.CD003032.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003032.pub5&amp;doi=10.1002/14651858.CD003032.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003032.pub5&amp;doi=10.1002/14651858.CD003032.pub5&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="kKvAiZoF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003032\x2epub5\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003032\x2epub5\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003032\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003032\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","th","ms","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003032.pub5",title:"Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents",firstPublishedDate:"Jan 21, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Epilepsy Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=kKvAiZoF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003032.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003032.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003032.pub5/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003032.pub5/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003032.pub5%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003032.PUB5" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003032.pub5/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003032.PUB5" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003032.pub5/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003032.pub5/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4380 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003032.pub5" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003032.pub5/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003032.pub5/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003032.pub5/full#CD003032-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003032.pub5/full#CD003032-sec-0072"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003032.pub5/full#CD003032-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003032.pub5/full#CD003032-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003032.pub5/full#CD003032-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003032.pub5/full#CD003032-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003032.pub5/full#CD003032-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003032.pub5/full#CD003032-sec-0065"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003032.pub5/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003032.pub5/appendices#CD003032-sec-0077"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003032.pub5/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003032.pub5/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/table_n/CD003032StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/table_n/CD003032StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003032.pub5/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003032.pub5/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003032.pub5/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003032.pub5/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003032.pub5/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003032.pub5/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003032.pub5/information#CD003032-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Francesco Brigo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003032.pub5/information#CD003032-cr-0005">Stanley C Igwe</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003032.pub5/information#CD003032-cr-0006">Simona Lattanzi</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/information/en#CD003032-sec-0083">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 January 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003032.pub5">https://doi.org/10.1002/14651858.CD003032.pub5</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003032-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003032-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003032-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003032-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003032-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/th#CD003032-abs-0005">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003032-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003032-abs-0001" lang="en"> <section id="CD003032-sec-0001"> <h3 class="title" id="CD003032-sec-0001">Background</h3> <p>This is an updated version of the Cochrane Review previously published in 2019.</p> <p>Absence seizures (AS) are brief epileptic seizures which present in childhood and adolescence. Depending on clinical features and electroencephalogram (EEG) findings they are divided into typical, atypical absences, and absences with special features. Typical absences are characterised by sudden loss of awareness and an EEG typically shows generalised spike wave discharges at three cycles per second. Ethosuximide, valproate and lamotrigine are currently used to treat absence seizures. This review aims to determine the best choice of antiepileptic drug for children and adolescents with AS. </p> </section> <section id="CD003032-sec-0002"> <h3 class="title" id="CD003032-sec-0002">Objectives</h3> <p>To review the evidence for the effects of ethosuximide, valproate and lamotrigine as treatments for children and adolescents with absence seizures (AS), when compared with placebo or each other. </p> </section> <section id="CD003032-sec-0003"> <h3 class="title" id="CD003032-sec-0003">Search methods</h3> <p>For the latest update we searched the Cochrane Register of Studies (CRS Web, 22 September 2020) and MEDLINE (Ovid, 1946 to September 21, 2020). CRS Web includes randomised or quasi‐randomised, controlled trials from PubMed, Embase, ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry Platform (ICTRP), the Cochrane Central Register of Controlled Trials (CENTRAL), and the Specialized Registers of Cochrane Review Groups including Epilepsy. No language restrictions were imposed. In addition, we contacted Sanofi Winthrop, Glaxo Wellcome (now GlaxoSmithKline) and Parke Davis (now Pfizer), manufacturers of sodium valproate, lamotrigine and ethosuximide respectively. </p> </section> <section id="CD003032-sec-0004"> <h3 class="title" id="CD003032-sec-0004">Selection criteria</h3> <p>Randomised parallel group monotherapy or add‐on trials which include a comparison of any of the following in children or adolescents with AS: ethosuximide, sodium valproate, lamotrigine, or placebo. </p> </section> <section id="CD003032-sec-0005"> <h3 class="title" id="CD003032-sec-0005">Data collection and analysis</h3> <p>Outcome measures were: 1. proportion of individuals seizure free at one, three, six, 12 and 18 months post randomisation; 2. individuals with a 50% or greater reduction in seizure frequency; 3. normalisation of EEG and/or negative hyperventilation test; and 4. adverse effects. Data were independently extracted by two review authors. Results are presented as risk ratios (RR) with 95% confidence intervals (95% CIs). We used GRADE quality assessment criteria to evaluate the certainty of evidence for the outcomes derived from all included studies. </p> </section> <section id="CD003032-sec-0006"> <h3 class="title" id="CD003032-sec-0006">Main results</h3> <p>On the basis of our selection criteria, we included no new studies in the present review. Eight small trials (total number of participants: 691) were included from the earlier review. Six of them were of poor methodological quality (unclear or high risk of bias) and seven recruited less than 50 participants. There are no placebo‐controlled trials for ethosuximide or valproate, and hence, no evidence from randomised controlled trials (RCTs) to support a specific effect on AS for either of these two drugs. Due to the differing methodologies used in the trials comparing ethosuximide, lamotrigine and valproate, we thought it inappropriate to undertake a meta‐analysis. One large randomised, parallel double‐blind controlled trial comparing ethosuximide, lamotrigine and sodium valproate in 453 children with newly diagnosed childhood absence epilepsy found that at 12 months, seizure freedom was higher in patients taking ethosuximide (70/154, 45%) than in patients taking lamotrigine (31/146, 21%; P &lt; 0.001), with no difference between valproate (64/146, 44%) and ethosuximide (70/154, 45%; P &gt; 0.05). </p> <p>In this study, the frequency of treatment failures due to intolerable adverse events was significantly different among the treatment groups, with the largest proportion of adverse events in the valproic acid group (48/146, 33%) compared to the ethosuximide (38/154, 25%) and the lamotrigine (29/146, 20%) groups (P &lt; 0.037). Overall, this large study demonstrates the superior effectiveness of ethosuximide and valproic acid compared to lamotrigine as initial monotherapy aimed to control seizures without intolerable adverse effects in children with childhood absence epilepsy. This study provided high certainty of the evidence for outcomes for which data were available. However, the certainty of the evidence provided by the other included studies was low, primarily due to risk of bias and imprecise results because of the small sample sizes. Hence, conclusions regarding the efficacy of ethosuximide, valproic acid and lamotrigine derive mostly from this single study. </p> </section> <section id="CD003032-sec-0007"> <h3 class="title" id="CD003032-sec-0007">Authors' conclusions</h3> <p>Since the last version of this review was published, we have found no new studies. Hence, the conclusions remain the same as the previous update. With regards to both efficacy and tolerability, ethosuximide represents the optimal initial empirical monotherapy for children and adolescents with AS. However, if absence and generalised tonic‐clonic seizures coexist, valproate should be preferred, as ethosuximide is probably inefficacious on tonic‐clonic seizures. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003032-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003032-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003032-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003032-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003032-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003032-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD003032-abs-0012">Polski</a> </li> <li class="section-language"> <a class="" href="full/th#CD003032-abs-0006">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD003032-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003032-abs-0002" lang="en"> <h3>Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents </h3> <p><b>Background</b> </p> <p>Epilepsy is a disorder where seizures are caused by abnormal electrical discharges from the brain. Absence epilepsy involves seizures that cause a sudden loss of awareness. It often starts in childhood or adolescence. Three antiepileptic drugs are often used for absence epilepsy: valproate, ethosuximide and lamotrigine. </p> <p>This review aims to determine which of these three antiepileptic drugs is the best choice for the treatment of absence seizures in children and adolescents. </p> <p><b>Results</b> </p> <p>The review found some evidence (based on eight small trials) that individuals taking lamotrigine are more likely to be seizure free than those using placebos. The review found robust evidence that patients taking ethosuximide or valproate are more likely to be seizure free than those using lamotrigine. However, because of the lower risk of adverse effects, the use of ethosuximide is preferred over valproate in patients with absence childhood epilepsy. </p> <p>With regards to both efficacy and tolerability, ethosuximide represents the optimal initial empirical monotherapy for children and adolescents with absence seizures. </p> <p>The evidence is current to September 2020.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003032-sec-0072" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003032-sec-0072"></div> <h3 class="title" id="CD003032-sec-0073">Implications for practice</h3> <section id="CD003032-sec-0073"> <p>Since the last version of this review was published, we have found no new studies. Hence, we have made no changes to the conclusions of this update as presented in the initial review. With regards to both efficacy and tolerability, ethosuximide represents the optimal initial empirical monotherapy for children and adolescents with absence seizures (AS). However, if absence and generalised tonic‐clonic seizures co‐exist, valproate should be preferred over ethosuximide, as this drug is probably inefficacious on tonic‐clonic seizures. These implications for practice rely on results of trials that were heterogeneous. Larger trials could further clarify or change implications for practice in the future. </p> </section> <h3 class="title" id="CD003032-sec-0074">Implications for research</h3> <section id="CD003032-sec-0074"> <p>We now have moderate to high evidence that ethosuximide and valproate have higher efficacy than lamotrigine as initial monotherapy in children and adolescents with AS, and that ethosuximide is better tolerated. Due to its good profile in terms of both efficacy and tolerability, ethosuximide should be considered as the standard treatment if only AS are present. However, if absence and generalised tonic‐clonic seizures co‐exist, valproate should be preferred. Placebo‐controlled trials in people with newly diagnosed epilepsy will provide evidence for an effect and aid in the interpretation of comparative studies should such studies find equivalence. However, clinical practice is best informed by trials that compare the effect of one drug with another. Such trials should be pragmatic in concept and given that AS are relatively common, they should also be feasible. If possible, future trials should be of a larger size than many of the studies currently included in this review. In addition, such trials will need to be of at least 12 months' duration and measure outcomes which include remission from seizures, EEG with a hyperventilation test, adverse effects, quality of life and psychosocial outcomes. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003032-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003032-sec-0008"></div> <div class="table" id="CD003032-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Ethosuximide compared to valproate for absence seizures in children and adolescents</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Ethosuximide compared to valproate for absence seizures in children and adolescents</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> absence seizures in children and adolescents<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> ethosuximide<br/><b>Comparison:</b> valproate </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with valproate</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ethosuximide</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Seizure freedom at 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>365<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>None of the included trials found a difference for this outcome.</p> <p>Length of follow‐up in included studies: from 6 weeks to 4 years.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>80% or greater reduction in seizure frequency</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.70<br/>(0.19 to 2.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>29<br/>(1 RCT)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No difference was found, but the confidence interval is wide and equivalence cannot be inferred. </p> <p>Length of follow‐up: 6 weeks.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>286 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1,000<br/>(54 to 740) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>50% or greater reduction in seizure frequency</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>49<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No difference was found, but the confidence interval is wide and equivalence cannot be inferred. </p> <p>Length of follow‐up in included studies: from 1 to 4 years.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normalisation of the EEG ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Adverse effects (<a href="./full#CD003032-tbl-0002">Table 1</a>; <a href="./full#CD003032-tbl-0003">Table 2</a>) </p> <p>Ethosuximide treatment was mostly associated with nausea, vomiting, and behavioural/psychiatric changes. </p> <p>The most common adverse effects of treatment with valproate were fatigue, nausea, vomiting, increased appetite with weight gain, behavioural/psychiatric changes (decreased concentration, personality change, hyperactivity, attention problems, hostility), and thrombocytopenia </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Most information is from studies at low or unclear risk of bias; plausible bias is likely to seriously alter the results. </p> <p><sup>2</sup> Information is from a study with unclear and high risk of bias; plausible bias is likely to seriously alter the results. </p> <p><sup>3</sup> Small number of patients included in this study (29) (see also footnote below). </p> <p><sup>4</sup> Information is from two small studies with unclear or high risk of bias; plausible bias is likely to seriously alter the results. </p> <p><sup>5</sup> Information is from two studies with small number of patients included. </p> <p><sup>a</sup>In this study, one patient in the ethosuximide group was subsequently treated with valproate, but failed to respond to either single drug and did not improve when both drugs were used in combination. The outcomes of this patient on combined treatment were therefore counted twice ("no remission"), since the patient received both drugs. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003032-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">1.</span> <span class="table-title">Adverse effects on valproate: number of participants experiencing each event</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Event</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0002" title="CallaghanN , O'HareJ , O'DriscollD , O'NeillB , DalyM . Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Developmental Medicine and Clinical Neurology1982;24(6):830-6. "><b>Callaghan 1982</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0008" title="SatoS , WhiteBG , PenryJK , DreifussFE , SackellaresJC , KupferbergHJ . Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology1982;32(2):157-63. "><b>Sato 1982</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0007" title="MartinovicZ . Comparison of ethosuximide with sodium valproate as monotherapies of absence seizures. In: ParsonageMJ , editors(s). Advances in Epileptology: XIVth Epilepsy International Symposium. New York: Raven Press, 1983:301-5. "><b>Martinovic 1983</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0003" title="CoppolaG , AuricchioG , FedericoR , CarotenutoM , PascottoA . Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia2004;45(9):1049-53. CoppolaG , LervolinoG , MastrosimoneM , La TorreG , RuiuF , PascottoA . Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development2004;26(6):373-6. "><b>Coppola 2004</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. "><b>Huang 2009</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. "><b>Glauser 2013a</b> </a> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute pancreatitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Obesity/Weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased platelet numbers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperactivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Attention problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hostility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Concentration decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Personality change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleep problem</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Slow process speed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Memory problem</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Apathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elevated liver function tests</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elevated LDH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*Nausea, vomiting, or both<br/>LDH: lactate dehydrogenase </p> <p>Numbers of individuals within each study undertaking valproate: 14 (<a href="./references#CD003032-bbs2-0002" title="CallaghanN , O'HareJ , O'DriscollD , O'NeillB , DalyM . Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Developmental Medicine and Clinical Neurology1982;24(6):830-6. ">Callaghan 1982</a>), 22 (<a href="./references#CD003032-bbs2-0008" title="SatoS , WhiteBG , PenryJK , DreifussFE , SackellaresJC , KupferbergHJ . Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology1982;32(2):157-63. ">Sato 1982</a>), 10 (<a href="./references#CD003032-bbs2-0007" title="MartinovicZ . Comparison of ethosuximide with sodium valproate as monotherapies of absence seizures. In: ParsonageMJ , editors(s). Advances in Epileptology: XIVth Epilepsy International Symposium. New York: Raven Press, 1983:301-5. ">Martinovic 1983</a>), 19 (<a href="./references#CD003032-bbs2-0003" title="CoppolaG , AuricchioG , FedericoR , CarotenutoM , PascottoA . Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia2004;45(9):1049-53. CoppolaG , LervolinoG , MastrosimoneM , La TorreG , RuiuF , PascottoA . Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development2004;26(6):373-6. ">Coppola 2004</a>), 23 (<a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. ">Huang 2009</a>), 146 (<a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a>). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003032-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">2.</span> <span class="table-title">Adverse effects on ethosuximide: number of participants experiencing each event</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Event</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0002" title="CallaghanN , O'HareJ , O'DriscollD , O'NeillB , DalyM . Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Developmental Medicine and Clinical Neurology1982;24(6):830-6. "><b>Callaghan 1982</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0008" title="SatoS , WhiteBG , PenryJK , DreifussFE , SackellaresJC , KupferbergHJ . Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology1982;32(2):157-63. "><b>Sato 1982</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0007" title="MartinovicZ . Comparison of ethosuximide with sodium valproate as monotherapies of absence seizures. In: ParsonageMJ , editors(s). Advances in Epileptology: XIVth Epilepsy International Symposium. New York: Raven Press, 1983:301-5. "><b>Martinovic 1983</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. "><b>Glauser 2013a</b> </a> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tiredness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hiccups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moodiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperactivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Attention problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hostility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Concentration decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Personality change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleep problem</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Slow process speed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Memory problem</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Apathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>* Nausea, vomiting, or both</p> <p>Numbers of individuals within each study undertaking ethosuximide: 14 (<a href="./references#CD003032-bbs2-0002" title="CallaghanN , O'HareJ , O'DriscollD , O'NeillB , DalyM . Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Developmental Medicine and Clinical Neurology1982;24(6):830-6. ">Callaghan 1982</a>), 23 (<a href="./references#CD003032-bbs2-0008" title="SatoS , WhiteBG , PenryJK , DreifussFE , SackellaresJC , KupferbergHJ . Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology1982;32(2):157-63. ">Sato 1982</a>), 10 (<a href="./references#CD003032-bbs2-0007" title="MartinovicZ . Comparison of ethosuximide with sodium valproate as monotherapies of absence seizures. In: ParsonageMJ , editors(s). Advances in Epileptology: XIVth Epilepsy International Symposium. New York: Raven Press, 1983:301-5. ">Martinovic 1983</a>), 154 (<a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a>). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003032-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Lamotrigine compared to valproate for absence seizures in children and adolescents</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Lamotrigine compared to valproate for absence seizures in children and adolescents</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> absence seizures in children and adolescents<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> lamotrigine<br/><b>Comparison:</b> valproate </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with valproate</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with lamotrigine</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Seizure freedom at 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>405<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Higher proportion seizure free at 1 month in patients receiving valproate compared to those receiving lamotrigine (2 studies). </p> <p>No difference between valproate and lamotrigine for seizure freedom at 3 and 6 months (3 and 4 studies, respectively). </p> <p>Length of follow‐up in included studies: 12 months.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80% or greater reduction in seizure frequency ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50% or greater reduction in seizure frequency ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Normalisation of the EEG</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.39<br/>(1.14 to 5.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>45<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Length of follow‐up: 12 months.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>273 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>652 per 1,000<br/>(311 to 1,000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Adverse effects (<a href="./full#CD003032-tbl-0002">Table 1</a>; <a href="./full#CD003032-tbl-0005">Table 3</a>) </p> <p>The most common adverse effects of treatment with lamotrigine were fatigue, and behavioural/psychiatric changes. </p> <p>The most common adverse effects of treatment with valproate were fatigue, nausea, vomiting, increased appetite with weight gain, behavioural/psychiatric changes (decreased concentration, personality change, hyperactivity, attention problems, hostility), and thrombocytopenia </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Most information comes from studies at low or unclear risk of bias; plausible bias is likely to seriously alter the results.<br/><sup>2</sup> Information comes from a small study at unclear and high risk of bias.<br/><sup>3</sup> Information comes from a single study conducted in a small number of patients. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003032-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">3.</span> <span class="table-title">Adverse effects on lamotrigine: number of participants experiencing each event</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Event</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0004" title="FrankLM , EnlowT , HolmesGL , ManascoP , ConcannonS , ChenC , et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia1999;40(7):973-9. FrankLM , MessenheimerJA , VuongA , WarnockCR . Childhood absence seizures: onset of treatment efficacy with lamotrigine [Abstract: Proceedings of the Annual Meeting of the American Epilepsy Society, New Orleans, Louisiana. December 3-7 2004. Abstract no 2.282]. Epilepsia2004;45(Suppl 7):320. "><b>Frank 1999</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0003" title="CoppolaG , AuricchioG , FedericoR , CarotenutoM , PascottoA . Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia2004;45(9):1049-53. CoppolaG , LervolinoG , MastrosimoneM , La TorreG , RuiuF , PascottoA . Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development2004;26(6):373-6. "><b>Coppola 2004</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. "><b>Huang 2009</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. "><b>Glauser 2013a</b> </a> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperactivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Attention problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hostility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Concentration decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Personality change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleep problem</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Slow process speed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Memory problem</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Apathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diplopia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>*Nausea, vomiting, or both</p> <p>Numbers of individuals within each study undertaking lamotrigine: 15 (<a href="./references#CD003032-bbs2-0004" title="FrankLM , EnlowT , HolmesGL , ManascoP , ConcannonS , ChenC , et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia1999;40(7):973-9. FrankLM , MessenheimerJA , VuongA , WarnockCR . Childhood absence seizures: onset of treatment efficacy with lamotrigine [Abstract: Proceedings of the Annual Meeting of the American Epilepsy Society, New Orleans, Louisiana. December 3-7 2004. Abstract no 2.282]. Epilepsia2004;45(Suppl 7):320. ">Frank 1999</a>), 19 (<a href="./references#CD003032-bbs2-0003" title="CoppolaG , AuricchioG , FedericoR , CarotenutoM , PascottoA . Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia2004;45(9):1049-53. CoppolaG , LervolinoG , MastrosimoneM , La TorreG , RuiuF , PascottoA . Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development2004;26(6):373-6. ">Coppola 2004</a>), 24 (<a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. ">Huang 2009</a>), 146 (<a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a>). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003032-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Ethosuximide compared to lamotrigine for absence seizures in children and adolescents</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Ethosuximide compared to lamotrigine for absence seizures in children and adolescents</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> absence seizures in children and adolescents<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> ethosuximide<br/><b>Comparison:</b> lamotrigine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with lamotrigine</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ethosuximide</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Seizure freedom at 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.47<br/>(0.33 to 0.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>300<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Length of follow‐up: 12 months.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>455 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>214 per 1,000<br/>(150 to 305) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80% or greater reduction in seizure frequency ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50% or greater reduction in seizure frequency ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normalisation of the EEG ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Adverse effects (<a href="./full#CD003032-tbl-0003">Table 2</a>; <a href="./full#CD003032-tbl-0005">Table 3</a>) </p> <p>Ethosuximide treatment was mostly associated with nausea, vomiting, and behavioural/psychiatric changes. </p> <p>The most common adverse effects of treatment with lamotrigine were fatigue, and behavioural/psychiatric changes. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003032-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003032-sec-0009"></div> <p>This is an updated version of the Cochrane Review previously published in 2019 (<a href="./references#CD003032-bbs2-0043" title="BrigoF , IgweSC , LattanziS . Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database of Systematic Reviews2019, Issue 2. Art. No: CD003032. [DOI: 10.1002/14651858.CD003032.pub4]">Brigo 2019</a>). </p> <section id="CD003032-sec-0010"> <h3 class="title" id="CD003032-sec-0010">Description of the condition</h3> <p>Absence seizures (AS) are brief epileptic seizures characterised by sudden loss of awareness. Depending on clinical features and electroencephalogram (EEG) findings, they are divided into typical AS, atypical AS, and AS with special features (<a href="./references#CD003032-bbs2-0026" title="BergAT , BerkovicSF , BrodieMJ , BuchhalterJ , CrossJH , vanEmde BoasW , et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia2010;51(4):676-85.">Berg 2010</a>; <a href="./references#CD003032-bbs2-0040" title="TenneyJR , GlauserTA . The current state of absence epilepsy: can we have your attention?Epilepsy Currents2013;13(3):135-40.">Tenney 2013</a>). About 10% of seizures in children with epilepsy are typical AS. Typical AS are associated with an EEG showing regular generalised and symmetrical spike and slow wave complexes at a frequency of three cycles per second at the same time as the absence. Childhood seizure disorders are classified into syndromes, which take into account seizure types, age and EEG changes. Typical AS may be the only seizure type experienced by a child and this then constitutes either an epileptic syndrome called childhood absence epilepsy or juvenile absence epilepsy. However, AS may also be only one of multiple types of seizures, for example in juvenile myoclonic epilepsy where myoclonic and tonic‐clonic seizures occur as well as AS. Atypical AS are characterised by less abrupt onset and offset, longer duration, changes in muscular tone, and variable impairment of consciousness; they are associated with interictal 1.5‐2.5 Hz irregular, asymmetrical spike and wave complexes on the EEG, and with diffuse, irregular slow spike and wave as ictal pattern. The 2010 revised International League Against Epilepsy (ILAE) Report on Terminology and Classification has recently recognised two additional types of AS, which are associated with special features: myoclonic AS and eyelid myoclonia with absence (EMA) (<a href="./references#CD003032-bbs2-0026" title="BergAT , BerkovicSF , BrodieMJ , BuchhalterJ , CrossJH , vanEmde BoasW , et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009. Epilepsia2010;51(4):676-85.">Berg 2010</a>). Seizures occurring in EMA are clinically associated with jerkings of the eyelids with upward eye‐deviation, which are usually triggered by eye closure; the ictal EEG shows 3‐6 Hz generalised polyspike and wave complexes, sometimes associated with occipital paroxysmal discharges. </p> </section> <section id="CD003032-sec-0011"> <h3 class="title" id="CD003032-sec-0011">Description of the intervention</h3> <p>Ethosuximide, valproic acid and lamotrigine are drugs commonly used for the treatment of children with AS. Ethosuximide was introduced into clinical practice in 1958, and is currently indicated only for the treatment of generalised AS; gastrointestinal side effects (nausea, vomiting, anorexia, and diarrhoea) occur in 4% to 29% of patients receiving ethosuximide (<a href="./references#CD003032-bbs2-0039" title="ShorvonS . Handbook of Epilepsy Treatment. 3 edition. Wiley-Blackwell, 2010.">Shorvon 2010</a>). Valproic acid is one of the most commonly prescribed antiepileptic drugs in the world, and thanks to its wide spectrum of activity, represents the drug of first choice for many types of epilepsy, including idiopathic generalised epilepsy; its risk of teratogenicity greatly limits its use in women of child‐bearing age (<a href="./references#CD003032-bbs2-0039" title="ShorvonS . Handbook of Epilepsy Treatment. 3 edition. Wiley-Blackwell, 2010.">Shorvon 2010</a>). Lamotrigine is a broad‐spectrum antiepileptic drug, which is used as add‐on or monotherapy of focal seizures and generalised seizures; it is generally effective and well tolerated, despite the risk of rash which can sometimes be severe, and complicated pharmacokinetics (<a href="./references#CD003032-bbs2-0039" title="ShorvonS . Handbook of Epilepsy Treatment. 3 edition. Wiley-Blackwell, 2010.">Shorvon 2010</a>). </p> </section> <section id="CD003032-sec-0012"> <h3 class="title" id="CD003032-sec-0012">How the intervention might work</h3> <p>The antiepileptic properties of ethosuximide and its efficacy against AS are due to its voltage‐dependent blockade of low‐threshold T‐ type calcium currents in the thalamus (<a href="./references#CD003032-bbs2-0039" title="ShorvonS . Handbook of Epilepsy Treatment. 3 edition. Wiley-Blackwell, 2010.">Shorvon 2010</a>). The mechanisms of action of valproate are various and not yet fully elucidated; it enhances inhibitory neurotransmission (mainly mediated by gamma‐Aminobutyric acid and glutamic acid), but it also reduces conductance at the voltage‐dependent sodium channel, as well as calcium (T) and potassium conductance (the latter mechanism may explain its efficacy against AS) (<a href="./references#CD003032-bbs2-0039" title="ShorvonS . Handbook of Epilepsy Treatment. 3 edition. Wiley-Blackwell, 2010.">Shorvon 2010</a>). Similar to carbamazepine or phenytoin, lamotrigine exerts its antiepileptic activity blocking voltage–dependent sodium channel conductance (<a href="./references#CD003032-bbs2-0039" title="ShorvonS . Handbook of Epilepsy Treatment. 3 edition. Wiley-Blackwell, 2010.">Shorvon 2010</a>). </p> </section> <section id="CD003032-sec-0013"> <h3 class="title" id="CD003032-sec-0013">Why it is important to do this review</h3> <p>Non‐systematic reviews have suggested that ethosuximide and sodium valproate are equally effective (<a href="./references#CD003032-bbs2-0030" title="DuncanJS . Treatment strategies for typical absences and related epileptic syndromes. In: DuncanJS , PanayiotopoulosCP , editors(s). Typical absences and related epileptic syndromes. London: Churchill Communications Europe, 1995.">Duncan 1995</a>). Valproate is considered the drug of choice in juvenile myoclonic epilepsy (<a href="./references#CD003032-bbs2-0028" title="ChadwickDW . Valproate monotherapy in the management of generalized and partial seizures. Epilepsia1987;28(Suppl 2):S12-7.">Chadwick 1987</a>; <a href="./references#CD003032-bbs2-0029" title="ChristeW . Valproate in juvenile myoclonic epilepsy. In: ChadwickD , editors(s). Fourth International Symposium on Sodium Valproate and Epilepsy. London: Royal Society of Medicine Services, 1989.">Christe 1989</a>), although there is little in the way of evidence from randomised controlled trials (RCTs) to support this. Lamotrigine used to be considered a second‐line drug, reserved for intractable AS (<a href="./references#CD003032-bbs2-0030" title="DuncanJS . Treatment strategies for typical absences and related epileptic syndromes. In: DuncanJS , PanayiotopoulosCP , editors(s). Typical absences and related epileptic syndromes. London: Churchill Communications Europe, 1995.">Duncan 1995</a>), but its use has increased with time. It is especially valued in situations where sodium valproate leads to weight gain and also for women of childbearing age. The latter is due to fears of a higher rate of fetal abnormalities in pregnancies exposed to valproate (<a href="./references#CD003032-bbs2-0036" title="MooreSJ , TurnpennyP , QuinnA , GloverS , LloydDJ , MontgomeryT , et al. A clinical study of 57 children with fetal anticonvulsant syndromes. Journal of Medical Genetics2000;37(7):489-97.">Moore 2000</a>). Preliminary studies suggested that lamotrigine may become the first‐line drug in AS (<a href="./references#CD003032-bbs2-0011" title="BuoniS , GrossoS , FoisA . Lamotrigine in typical absence epilepsy. Brain and Development1999;21:303-6. ">Buoni 1999</a>). This review aims to determine the best choice of anticonvulsant for children and adolescents with AS by reviewing the information available from RCTs. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003032-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003032-sec-0014"></div> <p>To review the evidence for the effects of ethosuximide, valproate and lamotrigine as treatments for children and adolescents with typical absence seizures (AS), when compared with placebo or each other. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003032-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003032-sec-0015"></div> <section id="CD003032-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003032-sec-0017"> <h4 class="title">Types of studies</h4> <p> <ol id="CD003032-list-0001"> <li> <p>Randomised parallel group monotherapy or add‐on trials which include a comparison of any of the following in children or adolescents with typical AS: ethosuximide; sodium valproate; lamotrigine and placebo. </p> </li> <li> <p>The studies should have used either adequate or quasi‐randomised methods (e.g. allocation by day of week). </p> </li> <li> <p>Blinded and unblinded studies.</p> </li> </ol> </p> </section> <section id="CD003032-sec-0018"> <h4 class="title">Types of participants</h4> <p>Children or adolescents (up to 16 years of age) with typical AS.</p> </section> <section id="CD003032-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Sodium valproate, ethosuximide or lamotrigine as monotherapy or add‐on treatment. These drugs may be compared with placebo or with one another. </p> </section> <section id="CD003032-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD003032-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD003032-list-0002"> <li> <p>Proportion of participants seizure free at one, three, six, 12 and 18 months after randomisation. </p> </li> <li> <p>Fifty per cent or greater reduction in the frequency of seizures.</p> </li> <li> <p>Incidence of adverse effects.</p> </li> </ol> </p> </section> <section id="CD003032-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD003032-list-0003"> <li> <p>Normalisation of electroencephalogram (EEG) and/or negative hyperventilation test.</p> </li> </ol> </p> </section> </section> </section> <section id="CD003032-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003032-sec-0024"> <h4 class="title">Electronic searches</h4> <p>Searches were run for the original review in March 2003 and subsequent searches were run in March 2005, July 2007, November 2009, August 2011, March 2014, December 2015, September 2016, and May 2018. </p> <p>For the latest update we searched:</p> <p> <ol id="CD003032-list-0004"> <li> <p>the Cochrane Register of Studies (CRS Web, 22 September 2020) using the search strategy shown in <a href="./appendices#CD003032-sec-0078">Appendix 1</a>; </p> </li> <li> <p>MEDLINE (Ovid, 1946 to September 21, 2020) using the search strategy shown in <a href="./appendices#CD003032-sec-0079">Appendix 2</a>. </p> </li> </ol> </p> <p>CRS Web includes randomised or quasi‐randomised, controlled trials from PubMed, Embase, ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry Platform (ICTRP), the Cochrane Central Register of Controlled Trials (CENTRAL), and the Specialized Registers of Cochrane Review Groups including Epilepsy. </p> <p>There were no language restrictions.</p> </section> <section id="CD003032-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We contacted Sanofi Winthrop, Glaxo Wellcome (now GlaxoSmithKline) and Parke Davis (now Pfizer), manufacturers of sodium valproate, lamotrigine and ethosuximide, respectively. We also reviewed any references of identified studies and retrieved any relevant studies. </p> </section> </section> <section id="CD003032-sec-0026"> <h3 class="title" id="CD003032-sec-0026">Data collection and analysis</h3> <section id="CD003032-sec-0027"> <h4 class="title">Selection of studies</h4> <p>Three review authors (FB, SI, SL) independently assessed trials for inclusion and disagreements were resolved by discussion. The same review authors independently extracted data from trial reports. </p> </section> <section id="CD003032-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>We extracted the following data from the studies that met our inclusion criteria:</p> <p> <ol id="CD003032-list-0005"> <li> <p>study design;</p> </li> <li> <p>method of randomisation concealment;</p> </li> <li> <p>method of blinding;</p> </li> <li> <p>whether any participants had been excluded from reported analyses;</p> </li> <li> <p>duration of treatment;</p> </li> <li> <p>outcome measures;</p> </li> <li> <p>participant data (total number of individuals allocated to each treatment group, age of participants, naive participants versus selected groups, individuals with other types of seizures co‐existing with typical absence seizures); </p> </li> <li> <p>results (success rate and adverse effects).</p> </li> </ol> </p> </section> <section id="CD003032-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (FB and SL) independently assessed risk of bias for each included trial using the Cochrane 'Risk of bias' tool (<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013028/references#CD013028-bbs2-0010" target="_blank">Higgins 2011</a>), considering sequence generation, concealment of allocation, methods of blinding, incomplete outcome data, selective reporting, and other types of bias. A third party resolved disagreements in the assessment of the level of bias. </p> </section> <section id="CD003032-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>The data for our chosen outcomes are dichotomous and our preferred outcome statistic was the risk ratio (RR). </p> </section> <section id="CD003032-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>We planned to deal with any unit of analysis issues according to the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013028/references#CD013028-bbs2-0010" target="_blank">Higgins 2011</a>). </p> </section> <section id="CD003032-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We conducted an intention‐to‐treat analysis. Due to the small number of included studies no best‐case or worst‐case analysis was performed. </p> </section> <section id="CD003032-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed clinical heterogeneity by evaluating similarities and differences in the methodologies and outcomes measured in the included studies and by visually inspecting forest plots. We planned to assess statistical heterogeneity using the Chi² test and I² statistic (<a href="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013028/references#CD013028-bbs2-0010" target="_blank">Higgins 2011</a>) as follows: 0% to 40% might not be important, 30% to 60% may represent moderate heterogeneity, 50% to 90% may represent substantial heterogeneity, and 75% to 100% indicating considerable heterogeneity. We used a fixed‐effect model if we did not find statistically significant heterogeneity between the included studies. Otherwise, we planned to use a random‐effects model. However, despite our primary intention, due to insufficient information on outcomes and too high clinical and methodological heterogeneity, we were unable to perform any meta‐analyses. </p> </section> <section id="CD003032-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We sought all protocols from study authors to identify any discrepancies between protocol and trial methodology. </p> </section> <section id="CD003032-sec-0035"> <h4 class="title">Data synthesis</h4> <p>Provided we thought it clinically appropriate, and no important heterogeneity was found, we planned to summarise results in a meta‐analysis. However, because of the methodological problems outlined below it was not possible to perform meta‐analysis of the data from the studies that fulfilled the inclusion criteria. The large difference in the length of follow‐up and timing of analysis was a particular problem. Further research could allow results to be pooled, leading to a quantitative rather than a qualitative summary of results. </p> </section> <section id="CD003032-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We did not carry out any subgroup analysis or formal investigation of heterogeneity.</p> </section> <section id="CD003032-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>If we had found trial methodologies to be sufficiently distinct, we would have conducted sensitivity analyses to identify which factor(s) could have influenced the degree of heterogeneity. </p> </section> <section id="CD003032-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>For the 2019 update, we presented the results concerning the outcomes of interest for which data were available from included studies in 'Summary of findings' tables, and we used GRADE (<a href="./references#CD003032-bbs2-0034" title="GuyattGH , OxmanAD , VistGE , KunzR , Falck-YtterY , Alonso-CoelloP , et al, GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ2008;336:924-6.">Guyatt 2008</a>) quality assessment criteria to evaluate the certainty of evidence for the outcomes derived from the studies included in this review. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003032-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003032-sec-0039"></div> <section id="CD003032-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD003032-sec-0041"> <h4 class="title">Results of the search</h4> <p>See <a href="#CD003032-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD003032-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram (results refer only to the updated version of the review). The previous versions of the review (Posner 2003; Posner 2005a; Posner 2005b; Brigo 2017; Brigo 2019) included eight studies." data-id="CD003032-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_n/nCD003032-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram (results refer only to the updated version of the review). The previous versions of the review (<a href="./references#CD003032-bbs2-0044" title="EB Posner, K Mohamed, AG MarsonTG . Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database of Systematic Reviews2003, Issue 3. Art. No: CD003032. [DOI: 10.1002/14651858.CD003032]">Posner 2003</a>; <a href="./references#CD003032-bbs2-0045" title="PosnerEB , MohamedK , MarsonAG . A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine. Seizure2005;14(2):117-22.">Posner 2005a</a>; <a href="./references#CD003032-bbs2-0046" title="PosnerEB , MohamedKK , MarsonAG . Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database of Systematic Reviews2005, Issue 4. Art. No: CD003032. [DOI: 10.1002/14651858.CD003032.pub2]">Posner 2005b</a>; <a href="./references#CD003032-bbs2-0042" title="BrigoF , IgweSC . Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: CD003032. [DOI: 10.1002/14651858.CD003032.pub3]">Brigo 2017</a>; <a href="./references#CD003032-bbs2-0043" title="BrigoF , IgweSC , LattanziS . Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database of Systematic Reviews2019, Issue 2. Art. No: CD003032. [DOI: 10.1002/14651858.CD003032.pub4]">Brigo 2019</a>) included eight studies. </p> </div> </div> </div> <p>The previous versions of the review (<a href="./references#CD003032-bbs2-0044" title="EB Posner, K Mohamed, AG MarsonTG . Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database of Systematic Reviews2003, Issue 3. Art. No: CD003032. [DOI: 10.1002/14651858.CD003032]">Posner 2003</a>; <a href="./references#CD003032-bbs2-0045" title="PosnerEB , MohamedK , MarsonAG . A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine. Seizure2005;14(2):117-22.">Posner 2005a</a>; <a href="./references#CD003032-bbs2-0046" title="PosnerEB , MohamedKK , MarsonAG . Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database of Systematic Reviews2005, Issue 4. Art. No: CD003032. [DOI: 10.1002/14651858.CD003032.pub2]">Posner 2005b</a>; <a href="./references#CD003032-bbs2-0042" title="BrigoF , IgweSC . Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: CD003032. [DOI: 10.1002/14651858.CD003032.pub3]">Brigo 2017</a>; <a href="./references#CD003032-bbs2-0043" title="BrigoF , IgweSC , LattanziS . Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database of Systematic Reviews2019, Issue 2. Art. No: CD003032. [DOI: 10.1002/14651858.CD003032.pub4]">Brigo 2019</a>) included eight studies. </p> <p>The updated search strategy described yielded 22 results (19 Cochrane Register of Studies (CRS Web), three MEDLINE). After removing one duplicate and 16 obviously irrelevant items, we assessed five articles for possible inclusion and excluded all of them. Since the last version of this review, we have found no new studies. Below we provide details of the studies included in the previous versions of this review. </p> </section> <section id="CD003032-sec-0042"> <h4 class="title">Included studies</h4> <p><a href="./references#CD003032-bbs2-0002" title="CallaghanN , O'HareJ , O'DriscollD , O'NeillB , DalyM . Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Developmental Medicine and Clinical Neurology1982;24(6):830-6. ">Callaghan 1982</a><br/>This was a randomised, parallel open study, which compared monotherapy with ethosuximide and sodium valproate. Ethosuximide was initially given at 250 mg/day and, whenever required, incremented by 250 mg to a maximum of 1500 mg/day. Valproate was started at 400 mg/day and, if deemed necessary, gradually incremented by 200 mg up to 2400 mg/day. Participants (total 28) had typical absence seizures (AS), were between four and 15 years, and were previously untreated. Follow‐up ranged from 18 months to four years. The report acknowledged support from Warner‐Lambert Pharmaceuticals, manufacturers of ethosuximide. </p> <p><a href="./references#CD003032-bbs2-0008" title="SatoS , WhiteBG , PenryJK , DreifussFE , SackellaresJC , KupferbergHJ . Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology1982;32(2):157-63. ">Sato 1982</a><br/>This study used a complex response‐conditional design and recruited drug‐naive participants as well as participants already on treatment, with a total of 45 participants recruited. In the first phase of this trial; participants were randomised to receive either valproate (and placebo) or ethosuximide (and placebo) and followed up for six weeks. Participants responding to randomised treatment continued with the randomised drug for a further six weeks. Responders included previously untreated participants who became seizure free and participants who had been previously treated and had an 80% or greater reduction in AS frequency. Non‐responders and those with adverse effects were crossed over to the alternative treatment and followed up for a further six weeks. The age range of participants was three to 18 years. Apart from AS, some participants also had other types of seizures. The report does not specify if the AS were typical or atypical. Some of the participants were drug naive and some drug resistant. Participants of the study were selected from those who attended the epilepsy clinic at the Clinical Research Center, University of Virginia Hospital, USA. The work was supported by a contract from the Institute of Neurological and Communicative Disorders and Stroke (NINCDS). </p> <p><a href="./references#CD003032-bbs2-0007" title="MartinovicZ . Comparison of ethosuximide with sodium valproate as monotherapies of absence seizures. In: ParsonageMJ , editors(s). Advances in Epileptology: XIVth Epilepsy International Symposium. New York: Raven Press, 1983:301-5. ">Martinovic 1983</a><br/>This was a parallel, open‐design study comparing ethosuximide and sodium valproate. Participants were between five and eight years old with a recent (less than six weeks) onset of seizures. All participants (total 20) had 'simple absences' and were followed up for one to two years. Six individuals did not co‐operate and were therefore not included in the analysis. No information about sponsorship by a pharmaceutical company is given. </p> <p><a href="./references#CD003032-bbs2-0004" title="FrankLM , EnlowT , HolmesGL , ManascoP , ConcannonS , ChenC , et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia1999;40(7):973-9. FrankLM , MessenheimerJA , VuongA , WarnockCR . Childhood absence seizures: onset of treatment efficacy with lamotrigine [Abstract: Proceedings of the Annual Meeting of the American Epilepsy Society, New Orleans, Louisiana. December 3-7 2004. Abstract no 2.282]. Epilepsia2004;45(Suppl 7):320. ">Frank 1999</a><br/>This was a double‐blind study using a 'responder enriched' design. Participants (total 29) had newly diagnosed typical AS and were aged between three to 15 years. Prior to randomisation, all participants received treatment with lamotrigine. After four weeks or more of treatment, participants who were seizure free and had a negative 24‐hour electroencephalogram (EEG) with hyperventilation, were randomised to either continue lamotrigine or to placebo and were followed up for four weeks. This study was sponsored by Glaxo Wellcome (now GlaxoSmithKline), makers of lamotrigine. </p> <p><a href="./references#CD003032-bbs2-0003" title="CoppolaG , AuricchioG , FedericoR , CarotenutoM , PascottoA . Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia2004;45(9):1049-53. CoppolaG , LervolinoG , MastrosimoneM , La TorreG , RuiuF , PascottoA . Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development2004;26(6):373-6. ">Coppola 2004</a><br/>This was a randomised, parallel group unblinded study comparing lamotrigine and sodium valproate. All participants (n = 38) were drug naive, aged three to 13 years old with typical AS. The follow‐up time was 12 months. The primary outcome measure was total seizure freedom, measured at one, three and 12 months. This study was not sponsored by any commercial organisation. </p> <p><a href="./references#CD003032-bbs2-0001" title="BasuS , BhattacharyyaKB , DasK , DasD . Comparative study of sodium valproate and lamotrigine as monotherapy in the management of typical absence seizures. Epilepsia2005;46(6):277. ">Basu 2005</a><br/>Results of this study were published as an abstract. We contacted the main author of this study via email three times (30 October and 4 November 2015, and 7 January 2016) asking for further information; we did not receive a reply. This was a randomised, open‐label, parallel group design comparing sodium valproate with lamotrigine used in monotherapy for treatment of typical AS (diagnosed clinically and by EEG support). Thirty patients were included (males 16; females 14 – aged between five and 14 years). Patients with other comorbidities were excluded. Fifteen patients were randomly allocated to receive valproate and 15 to receive lamotrigine. The follow‐up was 12 months. The primary outcome was seizure freedom and no EEG evidence of seizure. Drug dosages were not explicitly reported. The dosages were escalated according to the clinical response, starting from a low dose. Lamotrigine was titrated very slowly at two‐weekly intervals to avoid unwanted side effects (maximum 10 mg/kg/day). After one month of treatment nine patients (60%) receiving valproate and none (0%) receiving lamotrigine were seizure free. After three months, 11 patients (73.3%) in the sodium valproate and eight patients (53.3%) in the lamotrigine group receiving lamotrigine were seizure free. After 12 months, 12 patients (80%) receiving sodium valproate and 10 patients (66.6%) treated with lamotrigine were seizure free (P &gt; 0.05). Minimal adverse events (not explicitly reported) were observed in 26.6% of patients treated with sodium valproate and in 20% of patients receiving lamotrigine. No dropouts were observed. No information about sponsorship by a pharmaceutical company was available. </p> <p><a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. ">Huang 2009</a> </p> <p>This study (<a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. ">Huang 2009</a>), compared valproate with lamotrigine monotherapy in drug‐naive children (n = 48, six to 10 years) with newly diagnosed childhood AS (typical seizures). Included patients were 17 males and 31 females (no detailed descriptions in each group, respectively). The follow‐up time was 12 months. The outcome measure was total seizure freedom, measured at one, three, six and 12 months. Complete normalisation of EEG with seizure freedom and occurrence of adverse effects were also considered. In the valproate group, sustained‐release tablets or oral solution were administered twice daily (totally 15 mg/kg per day); in case of persisting seizures after one week, the dose was increased to 20 mg/kg per day, twice daily (maximum dose daily 30 mg/kg). In case of persisting seizures despite a maximum dose of 30 mg/kg within a month, combination with lamotrigine 0.15 mg/kg daily to 2 mg to 5 mg/kg was administrated. In the lamotrigine group, patients received a starting dose of lamotrigine of 0.5 mg/kg daily, administered twice, increased to 0.15 mg/kg per two weeks. The daily maintenance dose was 2 mg to 5 mg/kg, and the maximum daily dose 10 mg/kg. In case of persisting seizures despite a maximum dose within a month, combination with valproate 10 mg/kg daily to 20 mg/kg was administrated. No information about sponsorship by a pharmaceutical company was available. </p> <p><a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a><br/>This was a randomised, parallel double‐blind controlled trial comparing ethosuximide, lamotrigine and sodium valproate in children with newly diagnosed childhood absence epilepsy. The study design also included a partial cross‐over to open‐label (at treatment failure only) with subsequent follow‐up: participants reaching a treatment‐failure criterion in the double‐blind treatment phase were given the opportunity to enter into the open‐label phase, during which participants were randomised to one of the two other antiepileptic drugs. Participants (total 453 enrolled) had typical AS, were between seven months and 12 years 11 months, and were previously untreated. Among the 453 patients enrolled, seven were withdrawn, hence 446 participants were included in subsequent effectiveness analyses and 451 participants included in the safety analyses. Follow‐up was up to 12 months. Study drugs were titrated as tolerated in predetermined increments every one to two weeks over 16 weeks. Ethosuximide and valproic acid doses were incremented of 5 mg to 10 mg/kg/day at intervals of two weeks, whilst lamotrigine doses were incremented of 0.3 mg to 0.6 mg/kg/day at intervals of two weeks. The maximal target doses were ethosuximide 60 mg/kg/day or 2000 mg/day (whichever was lower), valproic acid 60 mg/kg/day or 3000 mg/day (whichever was lower), and lamotrigine 12 mg/kg/day or 600 mg/day (whichever was lower). The main effectiveness outcome was the freedom from treatment failure assessed 12 months after randomisation. Freedom from treatment failure was also assessed at 16 to 20 weeks. Treatment failure was defined as failure either due to lack of seizure control, or meeting safety exit criteria, or withdrawal from the study for any other reason. This study was not sponsored by any commercial organisation. </p> </section> <section id="CD003032-sec-0043"> <h4 class="title">Excluded studies</h4> <p>For this update, we excluded five studies for the following reasons: three studies were commentaries, one study was a review, and one study wasn't relevant to our current review. </p> </section> </section> <section id="CD003032-sec-0044"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD003032-fig-0002">Figure 2</a>; <a href="#CD003032-fig-0003">Figure 3</a>; <a href="./references#CD003032-sec-0089" title="">Characteristics of included studies</a>. </p> <div class="figure" id="CD003032-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003032-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_n/nCD003032-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD003032-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003032-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_n/nCD003032-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <p>Results of one study (<a href="./references#CD003032-bbs2-0001" title="BasuS , BhattacharyyaKB , DasK , DasD . Comparative study of sodium valproate and lamotrigine as monotherapy in the management of typical absence seizures. Epilepsia2005;46(6):277. ">Basu 2005</a>) were published as an abstract. Despite several attempts to contact the research authors to obtain more information on methodological issues and risk of bias, we received no reply. Thus, for this study there is an unclear risk of bias. </p> <p>Three of the included studies (<a href="./references#CD003032-bbs2-0002" title="CallaghanN , O'HareJ , O'DriscollD , O'NeillB , DalyM . Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Developmental Medicine and Clinical Neurology1982;24(6):830-6. ">Callaghan 1982</a>; <a href="./references#CD003032-bbs2-0008" title="SatoS , WhiteBG , PenryJK , DreifussFE , SackellaresJC , KupferbergHJ . Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology1982;32(2):157-63. ">Sato 1982</a>; <a href="./references#CD003032-bbs2-0007" title="MartinovicZ . Comparison of ethosuximide with sodium valproate as monotherapies of absence seizures. In: ParsonageMJ , editors(s). Advances in Epileptology: XIVth Epilepsy International Symposium. New York: Raven Press, 1983:301-5. ">Martinovic 1983</a>) date back 30 years and there was an obvious difference in the quality of the reporting in comparison with the newer studies (<a href="./references#CD003032-bbs2-0004" title="FrankLM , EnlowT , HolmesGL , ManascoP , ConcannonS , ChenC , et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia1999;40(7):973-9. FrankLM , MessenheimerJA , VuongA , WarnockCR . Childhood absence seizures: onset of treatment efficacy with lamotrigine [Abstract: Proceedings of the Annual Meeting of the American Epilepsy Society, New Orleans, Louisiana. December 3-7 2004. Abstract no 2.282]. Epilepsia2004;45(Suppl 7):320. ">Frank 1999</a>; <a href="./references#CD003032-bbs2-0003" title="CoppolaG , AuricchioG , FedericoR , CarotenutoM , PascottoA . Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia2004;45(9):1049-53. CoppolaG , LervolinoG , MastrosimoneM , La TorreG , RuiuF , PascottoA . Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development2004;26(6):373-6. ">Coppola 2004</a>; <a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. ">Huang 2009</a>; <a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a>). </p> <section id="CD003032-sec-0045"> <h4 class="title">Allocation</h4> <p>Only two of the studies described explicitly the methods of allocation concealment (<a href="./references#CD003032-bbs2-0003" title="CoppolaG , AuricchioG , FedericoR , CarotenutoM , PascottoA . Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia2004;45(9):1049-53. CoppolaG , LervolinoG , MastrosimoneM , La TorreG , RuiuF , PascottoA . Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development2004;26(6):373-6. ">Coppola 2004</a>; <a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a>). </p> </section> <section id="CD003032-sec-0046"> <h4 class="title">Blinding</h4> <p>The studies reported by Sato (<a href="./references#CD003032-bbs2-0008" title="SatoS , WhiteBG , PenryJK , DreifussFE , SackellaresJC , KupferbergHJ . Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology1982;32(2):157-63. ">Sato 1982</a>), Frank (<a href="./references#CD003032-bbs2-0004" title="FrankLM , EnlowT , HolmesGL , ManascoP , ConcannonS , ChenC , et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia1999;40(7):973-9. FrankLM , MessenheimerJA , VuongA , WarnockCR . Childhood absence seizures: onset of treatment efficacy with lamotrigine [Abstract: Proceedings of the Annual Meeting of the American Epilepsy Society, New Orleans, Louisiana. December 3-7 2004. Abstract no 2.282]. Epilepsia2004;45(Suppl 7):320. ">Frank 1999</a>), and Glauser (<a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a>) were double‐blinded, whilst the studies reported by Martinovic (<a href="./references#CD003032-bbs2-0007" title="MartinovicZ . Comparison of ethosuximide with sodium valproate as monotherapies of absence seizures. In: ParsonageMJ , editors(s). Advances in Epileptology: XIVth Epilepsy International Symposium. New York: Raven Press, 1983:301-5. ">Martinovic 1983</a>), Callaghan (<a href="./references#CD003032-bbs2-0002" title="CallaghanN , O'HareJ , O'DriscollD , O'NeillB , DalyM . Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Developmental Medicine and Clinical Neurology1982;24(6):830-6. ">Callaghan 1982</a>), Coppola (<a href="./references#CD003032-bbs2-0003" title="CoppolaG , AuricchioG , FedericoR , CarotenutoM , PascottoA . Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia2004;45(9):1049-53. CoppolaG , LervolinoG , MastrosimoneM , La TorreG , RuiuF , PascottoA . Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development2004;26(6):373-6. ">Coppola 2004</a>), and Huang (<a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. ">Huang 2009</a>) were unblinded (high risk of bias). In two out of the three double‐blinded studies, placebo and active drugs were indistinguishable (<a href="./references#CD003032-bbs2-0004" title="FrankLM , EnlowT , HolmesGL , ManascoP , ConcannonS , ChenC , et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia1999;40(7):973-9. FrankLM , MessenheimerJA , VuongA , WarnockCR . Childhood absence seizures: onset of treatment efficacy with lamotrigine [Abstract: Proceedings of the Annual Meeting of the American Epilepsy Society, New Orleans, Louisiana. December 3-7 2004. Abstract no 2.282]. Epilepsia2004;45(Suppl 7):320. ">Frank 1999</a>; <a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a>) and were considered to have a low risk of bias. </p> </section> <section id="CD003032-sec-0047"> <h4 class="title">Incomplete outcome data</h4> <p>Five studies described losses to follow‐up or exclusions from analyses. <a href="./references#CD003032-bbs2-0004" title="FrankLM , EnlowT , HolmesGL , ManascoP , ConcannonS , ChenC , et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia1999;40(7):973-9. FrankLM , MessenheimerJA , VuongA , WarnockCR . Childhood absence seizures: onset of treatment efficacy with lamotrigine [Abstract: Proceedings of the Annual Meeting of the American Epilepsy Society, New Orleans, Louisiana. December 3-7 2004. Abstract no 2.282]. Epilepsia2004;45(Suppl 7):320. ">Frank 1999</a> reports that one participant withdrew consent before treatment but after randomisation and that one participant did not comply but was included in the analysis. <a href="./references#CD003032-bbs2-0007" title="MartinovicZ . Comparison of ethosuximide with sodium valproate as monotherapies of absence seizures. In: ParsonageMJ , editors(s). Advances in Epileptology: XIVth Epilepsy International Symposium. New York: Raven Press, 1983:301-5. ">Martinovic 1983</a> reports that six of the initially recruited participants did not co‐operate and were not included in the analysis. <a href="./references#CD003032-bbs2-0003" title="CoppolaG , AuricchioG , FedericoR , CarotenutoM , PascottoA . Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia2004;45(9):1049-53. CoppolaG , LervolinoG , MastrosimoneM , La TorreG , RuiuF , PascottoA . Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development2004;26(6):373-6. ">Coppola 2004</a> reports loss of nine patients overall, all due to lack of efficacy, these patients exited the study at three months follow‐up; all randomised patients were included in the analysis. <a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. ">Huang 2009</a> reports that one patient in the valproate group was lost to follow‐up (no further specifications), whereas two patients in the lamotrigine group were withdrawn due to severe adverse effects (systemic anaphylaxis rash). <a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a> reports that among the 453 patients enrolled, seven were withdrawn due to ineligibility at baseline, so that 446 participants were included in subsequent effectiveness analyses and 451 participants in safety analyses. Two reports (<a href="./references#CD003032-bbs2-0002" title="CallaghanN , O'HareJ , O'DriscollD , O'NeillB , DalyM . Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Developmental Medicine and Clinical Neurology1982;24(6):830-6. ">Callaghan 1982</a>; <a href="./references#CD003032-bbs2-0008" title="SatoS , WhiteBG , PenryJK , DreifussFE , SackellaresJC , KupferbergHJ . Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology1982;32(2):157-63. ">Sato 1982</a>) did not make an explicit statement that participants were not lost to follow‐up or excluded from analyses. </p> </section> <section id="CD003032-sec-0048"> <h4 class="title">Selective reporting</h4> <p>Seven of the studies were assessed at low risk of bias (<a href="./references#CD003032-bbs2-0002" title="CallaghanN , O'HareJ , O'DriscollD , O'NeillB , DalyM . Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Developmental Medicine and Clinical Neurology1982;24(6):830-6. ">Callaghan 1982</a>; <a href="./references#CD003032-bbs2-0003" title="CoppolaG , AuricchioG , FedericoR , CarotenutoM , PascottoA . Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia2004;45(9):1049-53. CoppolaG , LervolinoG , MastrosimoneM , La TorreG , RuiuF , PascottoA . Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development2004;26(6):373-6. ">Coppola 2004</a>; <a href="./references#CD003032-bbs2-0004" title="FrankLM , EnlowT , HolmesGL , ManascoP , ConcannonS , ChenC , et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia1999;40(7):973-9. FrankLM , MessenheimerJA , VuongA , WarnockCR . Childhood absence seizures: onset of treatment efficacy with lamotrigine [Abstract: Proceedings of the Annual Meeting of the American Epilepsy Society, New Orleans, Louisiana. December 3-7 2004. Abstract no 2.282]. Epilepsia2004;45(Suppl 7):320. ">Frank 1999</a>; <a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a>; <a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. ">Huang 2009</a>; <a href="./references#CD003032-bbs2-0007" title="MartinovicZ . Comparison of ethosuximide with sodium valproate as monotherapies of absence seizures. In: ParsonageMJ , editors(s). Advances in Epileptology: XIVth Epilepsy International Symposium. New York: Raven Press, 1983:301-5. ">Martinovic 1983</a>; <a href="./references#CD003032-bbs2-0008" title="SatoS , WhiteBG , PenryJK , DreifussFE , SackellaresJC , KupferbergHJ . Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology1982;32(2):157-63. ">Sato 1982</a>); the remaining study was assessed at unclear risk of bias (<a href="./references#CD003032-bbs2-0001" title="BasuS , BhattacharyyaKB , DasK , DasD . Comparative study of sodium valproate and lamotrigine as monotherapy in the management of typical absence seizures. Epilepsia2005;46(6):277. ">Basu 2005</a>). </p> </section> </section> <section id="CD003032-sec-0049"> <h3 class="title" id="CD003032-sec-0049">Effects of interventions</h3> <p>See: <a href="./full#CD003032-tbl-0001"><b>Summary of findings 1</b> Ethosuximide compared to valproate for absence seizures in children and adolescents</a>; <a href="./full#CD003032-tbl-0004"><b>Summary of findings 2</b> Lamotrigine compared to valproate for absence seizures in children and adolescents</a>; <a href="./full#CD003032-tbl-0006"><b>Summary of findings 3</b> Ethosuximide compared to lamotrigine for absence seizures in children and adolescents</a> </p> <section id="CD003032-sec-0050"> <h4 class="title">Lamotrigine versus placebo</h4> <p>We found one study (<a href="./references#CD003032-bbs2-0004" title="FrankLM , EnlowT , HolmesGL , ManascoP , ConcannonS , ChenC , et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia1999;40(7):973-9. FrankLM , MessenheimerJA , VuongA , WarnockCR . Childhood absence seizures: onset of treatment efficacy with lamotrigine [Abstract: Proceedings of the Annual Meeting of the American Epilepsy Society, New Orleans, Louisiana. December 3-7 2004. Abstract no 2.282]. Epilepsia2004;45(Suppl 7):320. ">Frank 1999</a>) comparing lamotrigine with placebo which recruited 29 participants. As outlined in <a href="#CD003032-sec-0040">Description of studies</a> above, this trial used a responder‐enriched design where participants responding to lamotrigine during a pre‐randomisation baseline phase were randomised to continue lamotrigine or have it withdrawn. This trial therefore compares the effect of continuing versus withdrawing lamotrigine. The results were as follows: </p> <p> <ol id="CD003032-list-0006"> <li> <p>in the initial open‐label dose‐escalation phase, 71% of the participants became seizure free on lamotrigine using a 24‐hour EEG/video telemetry recording; </p> </li> <li> <p>in the placebo‐controlled phase 64% of the participants on lamotrigine remained seizure free versus 21% receiving placebo (P &lt; 0.03). </p> </li> </ol> </p> </section> <section id="CD003032-sec-0051"> <h4 class="title">Valproate versus placebo</h4> <p>We found no trials comparing valproate versus placebo.</p> </section> <section id="CD003032-sec-0052"> <h4 class="title">Ethosuximide versus placebo</h4> <p>We found no trials comparing ethosuximide versus placebo.</p> </section> <section id="CD003032-sec-0053"> <h4 class="title">Ethosuximide versus valproate</h4> <p>We found four studies comparing valproate with ethosuximide (<a href="./references#CD003032-bbs2-0002" title="CallaghanN , O'HareJ , O'DriscollD , O'NeillB , DalyM . Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Developmental Medicine and Clinical Neurology1982;24(6):830-6. ">Callaghan 1982</a>; <a href="./references#CD003032-bbs2-0008" title="SatoS , WhiteBG , PenryJK , DreifussFE , SackellaresJC , KupferbergHJ . Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology1982;32(2):157-63. ">Sato 1982</a>; <a href="./references#CD003032-bbs2-0007" title="MartinovicZ . Comparison of ethosuximide with sodium valproate as monotherapies of absence seizures. In: ParsonageMJ , editors(s). Advances in Epileptology: XIVth Epilepsy International Symposium. New York: Raven Press, 1983:301-5. ">Martinovic 1983</a>; <a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a>). Due to differences in study design, participants and length of follow‐up we did not think it appropriate to pool results in a meta‐analysis. For our chosen outcome 'seizure freedom', we were unable to extract data for this outcome at the time points we had specified (one, six and 18 months). Rather than not present any data for this outcome, we have summarised results for individual trials, where the proportion of participants seizure free during follow‐up was reported. Results for individual studies are presented below as well as in <a href="./references#CD003032-fig-0004" title="">Analysis 1.1</a>, <a href="./references#CD003032-fig-0005" title="">Analysis 1.2</a> and <a href="./references#CD003032-fig-0006" title="">Analysis 1.3</a>. </p> <section id="CD003032-sec-0054"> <h5 class="title">Seizure freedom</h5> <p>The risk ratio (RR) estimates with 95% confidence intervals (CIs) for seizure freedom (RR &lt; 1 favours ethosuximide) are (<a href="./references#CD003032-fig-0004" title="">Analysis 1.1</a>): </p> <p> <ol id="CD003032-list-0007"> <li> <p><a href="./references#CD003032-bbs2-0002" title="CallaghanN , O'HareJ , O'DriscollD , O'NeillB , DalyM . Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Developmental Medicine and Clinical Neurology1982;24(6):830-6. ">Callaghan 1982</a>: RR 0.70 (95% CI 0.32 to 1.51); seizure freedom was observed in six out of 15 patients receiving valproate and in eight out of 14 patients receiving ethosuximide. One patient in the ethosuximide group was subsequently treated with valproate, but failed to respond to either single drug and did not improve when both drugs were used in combination. The outcomes of this patient on combined treatment were therefore counted twice ("no remission"), since the patient received both drugs. </p> </li> <li> <p><a href="./references#CD003032-bbs2-0008" title="SatoS , WhiteBG , PenryJK , DreifussFE , SackellaresJC , KupferbergHJ . Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology1982;32(2):157-63. ">Sato 1982</a>: RR 1.93 (95% CI 0.87 to 4.25); seizure freedom was observed in six out of seven patients receiving valproate and in four out of nine patients receiving ethosuximide. </p> </li> <li> <p><a href="./references#CD003032-bbs2-0007" title="MartinovicZ . Comparison of ethosuximide with sodium valproate as monotherapies of absence seizures. In: ParsonageMJ , editors(s). Advances in Epileptology: XIVth Epilepsy International Symposium. New York: Raven Press, 1983:301-5. ">Martinovic 1983</a>: RR 0.88 (95% CI 0.53 to 1.46); seizure freedom was observed in seven out of 10 patients receiving valproate and in eight out of 10 patients receiving ethosuximide. </p> </li> <li> <p><a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a>: RR 0.96 (95% CI 0.75 to 1.24); seizure freedom was observed in 64 out of 146 patients receiving valproate and in 70 out of 154 patients receiving ethosuximide. </p> </li> </ol> </p> <p>Hence, none of these trials found a difference for this outcome. Adopting the GRADE methodology, we assessed the certainty of the evidence for this outcome from these studies as moderate (<a href="./full#CD003032-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD003032-sec-0055"> <h5 class="title">80% or greater reduction in seizure frequency</h5> <p>This outcome was only reported by <a href="./references#CD003032-bbs2-0008" title="SatoS , WhiteBG , PenryJK , DreifussFE , SackellaresJC , KupferbergHJ . Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology1982;32(2):157-63. ">Sato 1982</a>, and the RR was 0.70 (95% CI 0.19 to 2.59, <a href="./references#CD003032-fig-0005" title="">Analysis 1.2</a>); 80% or greater reduction in seizure frequency was observed in three out of 15 patients receiving valproate and in four out of 14 patients receiving ethosuximide. Again, no difference was found, but the confidence interval is wide and equivalence cannot be inferred. Adopting the GRADE methodology, we assessed the certainty of the evidence for this outcome as very low (<a href="./full#CD003032-tbl-0001">summary of findings Table 1</a>). </p> </section> <section id="CD003032-sec-0056"> <h5 class="title">50% or greater reduction in seizure frequency</h5> <p>This was reported for two trials (<a href="./references#CD003032-fig-0006" title="">Analysis 1.3</a>). In one trial (<a href="./references#CD003032-bbs2-0007" title="MartinovicZ . Comparison of ethosuximide with sodium valproate as monotherapies of absence seizures. In: ParsonageMJ , editors(s). Advances in Epileptology: XIVth Epilepsy International Symposium. New York: Raven Press, 1983:301-5. ">Martinovic 1983</a>), all participants achieved this outcome (10/10 in the valproate and 10/10 in the ethosuximide group). For the other trial (<a href="./references#CD003032-bbs2-0002" title="CallaghanN , O'HareJ , O'DriscollD , O'NeillB , DalyM . Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Developmental Medicine and Clinical Neurology1982;24(6):830-6. ">Callaghan 1982</a>) the RR was 1.02 (95% CI 0.70 to 1.48); 12 out of 15 patients receiving valproate and 11 out of 14 patients receiving ethosuximide experienced 50% or greater reduction in seizure frequency. Again, no difference is found, but the confidence interval is wide and equivalence cannot be inferred. In this study, one patient in the ethosuximide group was subsequently treated with valproate, but failed to respond to either single drug and did not improve when both drugs were used in combination. The outcomes of this patient on combined treatment were therefore counted twice ("no remission"). Adopting the GRADE methodology, we assessed the certainty of the evidence for this outcome as low (<a href="./full#CD003032-tbl-0001">summary of findings Table 1</a>). </p> </section> </section> <section id="CD003032-sec-0057"> <h4 class="title">Lamotrigine versus valproate</h4> <p>We found four studies comparing valproate with lamotrigine (<a href="./references#CD003032-bbs2-0003" title="CoppolaG , AuricchioG , FedericoR , CarotenutoM , PascottoA . Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia2004;45(9):1049-53. CoppolaG , LervolinoG , MastrosimoneM , La TorreG , RuiuF , PascottoA . Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development2004;26(6):373-6. ">Coppola 2004</a>; <a href="./references#CD003032-bbs2-0001" title="BasuS , BhattacharyyaKB , DasK , DasD . Comparative study of sodium valproate and lamotrigine as monotherapy in the management of typical absence seizures. Epilepsia2005;46(6):277. ">Basu 2005</a>; <a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. ">Huang 2009</a>; <a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a>). Due to differences in study design, participants and length of follow‐up, we did not think it appropriate to pool results in a meta‐analysis. For our chosen outcome 'seizure freedom', we were unable to extract data for this outcome at the time points we had specified (one, six and 18 months). Rather than not present any data for this outcome, we have summarised results for individual trials, where the proportion of participants seizures free during follow‐up was reported. Results for individual studies are presented below as well as in <a href="./references#CD003032-fig-0007" title="">Analysis 2.1</a> and <a href="./references#CD003032-fig-0008" title="">Analysis 2.2</a>. </p> <section id="CD003032-sec-0058"> <h5 class="title">Seizure freedom at one month</h5> <p>This outcome was reported in two trials (<a href="./references#CD003032-bbs2-0003" title="CoppolaG , AuricchioG , FedericoR , CarotenutoM , PascottoA . Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia2004;45(9):1049-53. CoppolaG , LervolinoG , MastrosimoneM , La TorreG , RuiuF , PascottoA . Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development2004;26(6):373-6. ">Coppola 2004</a>; <a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. ">Huang 2009</a>;). One study (<a href="./references#CD003032-bbs2-0003" title="CoppolaG , AuricchioG , FedericoR , CarotenutoM , PascottoA . Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia2004;45(9):1049-53. CoppolaG , LervolinoG , MastrosimoneM , La TorreG , RuiuF , PascottoA . Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development2004;26(6):373-6. ">Coppola 2004</a>) comparing valproate and lamotrigine head‐to‐head, recruited drug‐naive children with typical AS. The primary outcome measure was total seizure freedom and was assessed at one, three and 12 months. At one‐month follow‐up 52.6% of patients taking valproate (10 out of 19) were seizure free compared to only 5.3% of patients taking lamotrigine (one out of 19) (P = 0.004). The other study (<a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. ">Huang 2009</a>) compared valproate with lamotrigine monotherapy in drug‐naive children with newly diagnosed childhood As (typical seizures). After one month of treatment 16/23 patients (74%) receiving valproate and 2/22 (41%) receiving lamotrigine were seizure free. </p> </section> <section id="CD003032-sec-0059"> <h5 class="title">Seizure freedom at three months</h5> <p>This outcome was reported in three trials (<a href="./references#CD003032-bbs2-0003" title="CoppolaG , AuricchioG , FedericoR , CarotenutoM , PascottoA . Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia2004;45(9):1049-53. CoppolaG , LervolinoG , MastrosimoneM , La TorreG , RuiuF , PascottoA . Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development2004;26(6):373-6. ">Coppola 2004</a>; <a href="./references#CD003032-bbs2-0001" title="BasuS , BhattacharyyaKB , DasK , DasD . Comparative study of sodium valproate and lamotrigine as monotherapy in the management of typical absence seizures. Epilepsia2005;46(6):277. ">Basu 2005</a>; <a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. ">Huang 2009</a>;). In the first study (<a href="./references#CD003032-bbs2-0003" title="CoppolaG , AuricchioG , FedericoR , CarotenutoM , PascottoA . Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia2004;45(9):1049-53. CoppolaG , LervolinoG , MastrosimoneM , La TorreG , RuiuF , PascottoA . Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development2004;26(6):373-6. ">Coppola 2004</a>), at three months seizure freedom was observed in 12 out of 19 (63.1%) patients taking sodium valproate and in seven out of 19 (36.8%) patients taking lamotrigine (P = 0.19). In one study (<a href="./references#CD003032-bbs2-0001" title="BasuS , BhattacharyyaKB , DasK , DasD . Comparative study of sodium valproate and lamotrigine as monotherapy in the management of typical absence seizures. Epilepsia2005;46(6):277. ">Basu 2005</a>) after three months, 11 patients out of 15 (73.3%) in the sodium valproate and eight patients out of 15 (53.3%) in the lamotrigine group receiving lamotrigine were seizure free. In the third study (<a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. ">Huang 2009</a>), 17/23 patients (70%) receiving valproate and 9/22 (9%) receiving lamotrigine were seizure free at three months. </p> </section> <section id="CD003032-sec-0060"> <h5 class="title">Seizure freedom at six months</h5> <p>Only one study (<a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. ">Huang 2009</a>) reported data on this outcome: 17/24 patients (71%) receiving valproate and 12/24 (50%) receiving lamotrigine were seizure free at six months. </p> </section> <section id="CD003032-sec-0061"> <h5 class="title">Seizure freedom at 12 months</h5> <p>This outcome was reported for four trials (<a href="./references#CD003032-bbs2-0003" title="CoppolaG , AuricchioG , FedericoR , CarotenutoM , PascottoA . Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia2004;45(9):1049-53. CoppolaG , LervolinoG , MastrosimoneM , La TorreG , RuiuF , PascottoA . Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development2004;26(6):373-6. ">Coppola 2004</a>; <a href="./references#CD003032-bbs2-0001" title="BasuS , BhattacharyyaKB , DasK , DasD . Comparative study of sodium valproate and lamotrigine as monotherapy in the management of typical absence seizures. Epilepsia2005;46(6):277. ">Basu 2005</a>; <a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. ">Huang 2009</a>; <a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a>). The RR estimates with 95% CIs for seizure freedom (RR &lt; 1 favours lamotrigine) at 12 months are (<a href="./references#CD003032-fig-0007" title="">Analysis 2.1</a>): </p> <p> <ol id="CD003032-list-0008"> <li> <p><a href="./references#CD003032-bbs2-0003" title="CoppolaG , AuricchioG , FedericoR , CarotenutoM , PascottoA . Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia2004;45(9):1049-53. CoppolaG , LervolinoG , MastrosimoneM , La TorreG , RuiuF , PascottoA . Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development2004;26(6):373-6. ">Coppola 2004</a>: 1.30 (95% CI 0.77 to 2.20); seizure freedom was observed in 13 out of 19 patients receiving valproate and in 10 out of 19 patients receiving lamotrigine. </p> </li> <li> <p><a href="./references#CD003032-bbs2-0001" title="BasuS , BhattacharyyaKB , DasK , DasD . Comparative study of sodium valproate and lamotrigine as monotherapy in the management of typical absence seizures. Epilepsia2005;46(6):277. ">Basu 2005</a>: 1.20 (95% CI 0.77 to 1.86); seizure freedom was observed in 12 out of 15 patients receiving valproate and in 10 out of 15 patients receiving lamotrigine. </p> </li> <li> <p><a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. ">Huang 2009</a>: 1.36 (95% CI 0.86 to 2.13); seizure freedom was observed in 17 out of 23 patients receiving valproate and in 12 out of 22 patients receiving lamotrigine. </p> </li> <li> <p><a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a>: 2.06 (95% CI 1.44 to 2.97); seizure freedom was observed in 64 out of 146 patients receiving valproate and in 31 out of 146 patients receiving lamotrigine. </p> </li> </ol> </p> <p>Hence, none of these trials found a difference for this outcome. However, confidence intervals are all wide and the possibility of important differences has not been excluded and equivalence cannot be inferred. Adopting the GRADE methodology, we assessed the certainty of the evidence on this outcome from included studies as moderate (<a href="./full#CD003032-tbl-0004">summary of findings Table 2</a>). </p> </section> <section id="CD003032-sec-0062"> <h5 class="title">Normalisation of the EEG</h5> <p>Only one study (<a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. ">Huang 2009</a>) explicitly reported data on this outcome. The proportion showing normal EEG at 12 months in the lamotrigine group (6/22, 27.3%) was significantly lower than that in the valproic acid group (15/23, 65.2%) (P &lt; 0.05); RR = 2.39 (95% CI: 1.14 to 5.04; P = 0.0218). Adopting the GRADE methodology, we assessed the certainty of the evidence for this outcome as very low (<a href="./full#CD003032-tbl-0004">summary of findings Table 2</a>). </p> </section> </section> <section id="CD003032-sec-0063"> <h4 class="title">Ethosuximide versus lamotrigine</h4> <p>One study (<a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a>), compared ethosuximide and lamotrigine in drug‐naive patients with childhood AS. The main effectiveness outcome was the freedom from treatment failure assessed 12 months after randomisation. Freedom from treatment failure was also assessed at 16 to 20 weeks, and in between 16 and 20 weeks and month 12. Treatment failure was defined as failure either due to lack of seizure control, or meeting safety exit criteria, or withdrawal from the study for any other reason. Seizure freedom at 12 months after randomisation was higher in patients taking ethosuximide (70/154, 45%) than in patients taking lamotrigine (31/146, 21%; P &lt; 0.001). At 16 to 20 weeks, freedom from treatment failure was observed in 81/154 (53%) patients taking ethosuximide and 43/146 (29%) patients taking lamotrigine. Adopting the GRADE methodology, we assessed the certainty of the evidence for seizure freedom at 12 months as high (<a href="./full#CD003032-tbl-0006">summary of findings Table 3</a>). </p> </section> <section id="CD003032-sec-0064"> <h4 class="title">Adverse effects related to the use of ethosuximide, sodium valproate or lamotrigine</h4> <p>This section and the related tables apply to all studies and comparisons.</p> <p>The most common adverse effects of treatment with valproate reported by the studies assessing this drug (<a href="./references#CD003032-bbs2-0002" title="CallaghanN , O'HareJ , O'DriscollD , O'NeillB , DalyM . Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Developmental Medicine and Clinical Neurology1982;24(6):830-6. ">Callaghan 1982</a>; <a href="./references#CD003032-bbs2-0008" title="SatoS , WhiteBG , PenryJK , DreifussFE , SackellaresJC , KupferbergHJ . Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology1982;32(2):157-63. ">Sato 1982</a>; <a href="./references#CD003032-bbs2-0007" title="MartinovicZ . Comparison of ethosuximide with sodium valproate as monotherapies of absence seizures. In: ParsonageMJ , editors(s). Advances in Epileptology: XIVth Epilepsy International Symposium. New York: Raven Press, 1983:301-5. ">Martinovic 1983</a>; <a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. ">Huang 2009</a>; <a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a>) were fatigue, nausea, vomiting, increased appetite with weight gain, behavioural/psychiatric changes (decreased concentration, personality change, hyperactivity, attention problems, hostility), and thrombocytopenia (<a href="./full#CD003032-tbl-0002">Table 1</a>). </p> <p>Ethosuximide treatment was mostly associated with nausea, vomiting, and behavioural/psychiatric changes (<a href="./full#CD003032-tbl-0003">Table 2</a>). </p> <p>The most common adverse effects of treatment with lamotrigine were fatigue, and behavioural/psychiatric changes (<a href="./full#CD003032-tbl-0005">Table 3</a>). In one lamotrigine study (<a href="./references#CD003032-bbs2-0004" title="FrankLM , EnlowT , HolmesGL , ManascoP , ConcannonS , ChenC , et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia1999;40(7):973-9. FrankLM , MessenheimerJA , VuongA , WarnockCR . Childhood absence seizures: onset of treatment efficacy with lamotrigine [Abstract: Proceedings of the Annual Meeting of the American Epilepsy Society, New Orleans, Louisiana. December 3-7 2004. Abstract no 2.282]. Epilepsia2004;45(Suppl 7):320. ">Frank 1999</a>), the most commonly reported adverse event was rash (reported on 11 occasions in 10 patients). However, only in one of the individuals was this thought to be related to lamotrigine. There were two serious adverse events during the treatment, but they were judged to be unrelated to treatment. In one study (<a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. ">Huang 2009</a>), systemic anaphylaxis rash during lamotrigine treatment led to patients' withdrawal from the study. In the <a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a> study, no side effects (including rash, reported in two patients taking valproate, six patients taking ethosuximide, and six patients taking lamotrigine) occurred more frequently in the lamotrigine cohort compared to the other treatment groups (valproate and ethosuximide). In this study, the frequency of treatment failures due to intolerable adverse events was significantly different among the treatment groups, with the largest proportion of proportion of adverse events in the valproic acid group (48/146, 33%) compared to the ethosuximide (38/154, 25%) and the lamotrigine (29/146, 20%) groups (P &lt; 0.037). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003032-sec-0065" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003032-sec-0065"></div> <section id="CD003032-sec-0066"> <h3 class="title" id="CD003032-sec-0066">Summary of main results</h3> <p>Since the last version of this review was published, we have found no new studies. Hence we have made no changes to the conclusions of this update as presented in the last updated version of this review (<a href="./references#CD003032-bbs2-0043" title="BrigoF , IgweSC , LattanziS . Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database of Systematic Reviews2019, Issue 2. Art. No: CD003032. [DOI: 10.1002/14651858.CD003032.pub4]">Brigo 2019</a>). </p> <p>Despite absence seizures (AS) being a relatively common seizure type in children, we found only eight randomised controlled trials, seven of them recruiting 20 to 48 participants. Only the study of <a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a> included a much larger sample. </p> <p>One trial compared lamotrigine with placebo (<a href="./references#CD003032-bbs2-0004" title="FrankLM , EnlowT , HolmesGL , ManascoP , ConcannonS , ChenC , et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia1999;40(7):973-9. FrankLM , MessenheimerJA , VuongA , WarnockCR . Childhood absence seizures: onset of treatment efficacy with lamotrigine [Abstract: Proceedings of the Annual Meeting of the American Epilepsy Society, New Orleans, Louisiana. December 3-7 2004. Abstract no 2.282]. Epilepsia2004;45(Suppl 7):320. ">Frank 1999</a>), three compared ethosuximide with valproate (<a href="./references#CD003032-bbs2-0002" title="CallaghanN , O'HareJ , O'DriscollD , O'NeillB , DalyM . Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Developmental Medicine and Clinical Neurology1982;24(6):830-6. ">Callaghan 1982</a>; <a href="./references#CD003032-bbs2-0008" title="SatoS , WhiteBG , PenryJK , DreifussFE , SackellaresJC , KupferbergHJ . Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology1982;32(2):157-63. ">Sato 1982</a>; <a href="./references#CD003032-bbs2-0007" title="MartinovicZ . Comparison of ethosuximide with sodium valproate as monotherapies of absence seizures. In: ParsonageMJ , editors(s). Advances in Epileptology: XIVth Epilepsy International Symposium. New York: Raven Press, 1983:301-5. ">Martinovic 1983</a>), three compared lamotrigine with valproate (<a href="./references#CD003032-bbs2-0003" title="CoppolaG , AuricchioG , FedericoR , CarotenutoM , PascottoA . Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia2004;45(9):1049-53. CoppolaG , LervolinoG , MastrosimoneM , La TorreG , RuiuF , PascottoA . Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development2004;26(6):373-6. ">Coppola 2004</a>; <a href="./references#CD003032-bbs2-0001" title="BasuS , BhattacharyyaKB , DasK , DasD . Comparative study of sodium valproate and lamotrigine as monotherapy in the management of typical absence seizures. Epilepsia2005;46(6):277. ">Basu 2005</a>; <a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. ">Huang 2009</a>), and one compared ethosuximide, valproate, and lamotrigine (<a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a>). </p> <p>The trial comparing lamotrigine with placebo (<a href="./references#CD003032-bbs2-0004" title="FrankLM , EnlowT , HolmesGL , ManascoP , ConcannonS , ChenC , et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia1999;40(7):973-9. FrankLM , MessenheimerJA , VuongA , WarnockCR . Childhood absence seizures: onset of treatment efficacy with lamotrigine [Abstract: Proceedings of the Annual Meeting of the American Epilepsy Society, New Orleans, Louisiana. December 3-7 2004. Abstract no 2.282]. Epilepsia2004;45(Suppl 7):320. ">Frank 1999</a>), found that individuals becoming seizure free on lamotrigine, were more likely to remain seizure free if they were randomised to stay on lamotrigine rather than placebo. In essence, this trial assessed the effect of lamotrigine withdrawal. Although this trial finds evidence of an effect of lamotrigine on AS, it was of only four weeks duration, and the design is inadequate to inform clinical practice. Also, clinicians and people living with epilepsy are likely more concerned with how drugs compare with each other rather than with placebo. </p> <p>Three studies (<a href="./references#CD003032-bbs2-0003" title="CoppolaG , AuricchioG , FedericoR , CarotenutoM , PascottoA . Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia2004;45(9):1049-53. CoppolaG , LervolinoG , MastrosimoneM , La TorreG , RuiuF , PascottoA . Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development2004;26(6):373-6. ">Coppola 2004</a>; <a href="./references#CD003032-bbs2-0001" title="BasuS , BhattacharyyaKB , DasK , DasD . Comparative study of sodium valproate and lamotrigine as monotherapy in the management of typical absence seizures. Epilepsia2005;46(6):277. ">Basu 2005</a>; <a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. ">Huang 2009</a>) directly compared lamotrigine with the long‐established treatment for typical AS, sodium valproate. All three studies found both valproate and lamotrigine to be efficacious in the treatment of typical AS in children. However, in these studies, the study sample size was small (38, 30 and 48 patients, respectively), and estimates are therefore imprecise. </p> <p>Most robust results are provided by the much larger study including three groups: valproic acid, lamotrigine and ethosuximide (<a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a>). This study found that at 12 months, the freedom‐from‐failure rates for ethosuximide and valproic acid were similar and were higher than the rate for lamotrigine. The frequency of treatment failures due to lack of seizure control (P &lt; 0.001) and intolerable adverse events (P &lt; 0.037) was significantly different among the treatment groups. Almost two thirds of the 125 participants with treatment failure due to lack of seizure control were in the lamotrigine cohort. The largest subgroup (42%) of the 115 participants discontinuing due to adverse events was in the valproic acid group. Overall, this study demonstrates the superior effectiveness of ethosuximide and valproic acid compared to lamotrigine as initial monotherapy aimed to control seizures without intolerable adverse events in children with childhood absence epilepsy. Because of the higher rate of adverse events leading to drug discontinuation and the significant negative effects on attentional measures seen in the valproate cohort, the authors concluded that ethosuximide represents the optimal initial empirical monotherapy for childhood absence epilepsy. Notably, this study was the very first randomised controlled trial (RCT) to meet the International League Against Epilepsy (ILAE) criteria for class I evidence for childhood absence epilepsy (or for any type of generalised seizure in adults or children) (<a href="./references#CD003032-bbs2-0032" title="GlauserT , Ben-MenachemE , BourgeoisB , CnaanA , ChadwickD , GuerreiroC , et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia2006;47:1094-120.">Glauser 2006</a>). Consequently, ethosuximide and valproate were designed/designated as treatments with level A evidence in children with childhood absence epilepsy in the recent ILAE treatment guidelines (<a href="./references#CD003032-bbs2-0033" title="GlauserT , Ben-MenachemE , BourgeoisB , CnaanA , GuerreiroC , KälviäinenR , et al, ILAE Subcommission on AED Guidelines. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia2013;54:551-63.">Glauser 2013b</a>). Data on tolerability of valproate reported in the included studies are consistent with the general adverse‐effects profile of this drug. Adverse effects often seen with valproate treatment are dyspepsia, weight gain, tremor, transient hair loss and haematological abnormalities (<a href="./references#CD003032-bbs2-0037" title="Panayiotopoulos CP . Treatment of typical absence seizures and related epileptic syndromes. Paediatric Drugs2001;3(5):379-403.">Panayiotopoulos 2001</a>). The occurrence of rash in patients receiving lamotrigine is a well‐known adverse event of this drug and its risk may be reduced by slow titration (<a href="./references#CD003032-bbs2-0041" title="WangXQ , XiongJ , XuWH , YuSY , HuangXS , ZhangJT , et al. Risk of a lamotrigine-related skin rash: current meta-analysis and postmarketing cohort analysis. Seizure2015;25:52-61.">Wang 2015</a>). </p> </section> <section id="CD003032-sec-0067"> <h3 class="title" id="CD003032-sec-0067">Overall completeness and applicability of evidence</h3> <p>Evidence on the efficacy of ethosuximide, valproic acid and lamotrigine derive mostly from the large and high‐quality RCT conducted in the United States of America by <a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a>. Absence seizures are due to a genetic predisposition and not likely to be influenced by different socioeconomic environments. However, data on efficacy from this RCT should be replicated by further studies in middle‐ and low‐income countries to evaluate the worldwide generalisability of these results. </p> </section> <section id="CD003032-sec-0068"> <h3 class="title" id="CD003032-sec-0068">Quality of the evidence</h3> <p>The description of important methodology was sometimes poor, and only two studies (<a href="./references#CD003032-bbs2-0003" title="CoppolaG , AuricchioG , FedericoR , CarotenutoM , PascottoA . Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia2004;45(9):1049-53. CoppolaG , LervolinoG , MastrosimoneM , La TorreG , RuiuF , PascottoA . Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development2004;26(6):373-6. ">Coppola 2004</a>; <a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a>) gave a description of allocation concealment. Three of the trials were explicitly reported as double‐blind (<a href="./references#CD003032-bbs2-0008" title="SatoS , WhiteBG , PenryJK , DreifussFE , SackellaresJC , KupferbergHJ . Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology1982;32(2):157-63. ">Sato 1982</a>; <a href="./references#CD003032-bbs2-0004" title="FrankLM , EnlowT , HolmesGL , ManascoP , ConcannonS , ChenC , et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia1999;40(7):973-9. FrankLM , MessenheimerJA , VuongA , WarnockCR . Childhood absence seizures: onset of treatment efficacy with lamotrigine [Abstract: Proceedings of the Annual Meeting of the American Epilepsy Society, New Orleans, Louisiana. December 3-7 2004. Abstract no 2.282]. Epilepsia2004;45(Suppl 7):320. ">Frank 1999</a>; <a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a>). In three of the trials there was no mention of losses to follow‐up or exclusions from analyses. The trials used a variety of methodologies; six were parallel trials (<a href="./references#CD003032-bbs2-0002" title="CallaghanN , O'HareJ , O'DriscollD , O'NeillB , DalyM . Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Developmental Medicine and Clinical Neurology1982;24(6):830-6. ">Callaghan 1982</a>; <a href="./references#CD003032-bbs2-0007" title="MartinovicZ . Comparison of ethosuximide with sodium valproate as monotherapies of absence seizures. In: ParsonageMJ , editors(s). Advances in Epileptology: XIVth Epilepsy International Symposium. New York: Raven Press, 1983:301-5. ">Martinovic 1983</a>; <a href="./references#CD003032-bbs2-0003" title="CoppolaG , AuricchioG , FedericoR , CarotenutoM , PascottoA . Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia2004;45(9):1049-53. CoppolaG , LervolinoG , MastrosimoneM , La TorreG , RuiuF , PascottoA . Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development2004;26(6):373-6. ">Coppola 2004</a>; <a href="./references#CD003032-bbs2-0001" title="BasuS , BhattacharyyaKB , DasK , DasD . Comparative study of sodium valproate and lamotrigine as monotherapy in the management of typical absence seizures. Epilepsia2005;46(6):277. ">Basu 2005</a>; <a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. ">Huang 2009</a>; <a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a>) and two used response conditional designs (<a href="./references#CD003032-bbs2-0008" title="SatoS , WhiteBG , PenryJK , DreifussFE , SackellaresJC , KupferbergHJ . Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology1982;32(2):157-63. ">Sato 1982</a>; <a href="./references#CD003032-bbs2-0007" title="MartinovicZ . Comparison of ethosuximide with sodium valproate as monotherapies of absence seizures. In: ParsonageMJ , editors(s). Advances in Epileptology: XIVth Epilepsy International Symposium. New York: Raven Press, 1983:301-5. ">Martinovic 1983</a>). The length of follow‐up ranged from four weeks to four years. </p> <p>Using GRADE, we assessed the certainty of the evidence to be very low to high for outcomes for which data were available. The reasons for these judgements are outlined in the <a href="./full#CD003032-tbl-0001">summary of findings Table 1</a>; <a href="./full#CD003032-tbl-0004">summary of findings Table 2</a>; <a href="./full#CD003032-tbl-0006">summary of findings Table 3</a>. We assessed the study of <a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a> as being at low risk of bias, and providing high certainty of the evidence for outcomes for which data were available. However, the certainty of the evidence provided by the other included studies was low, primarily due to risk of bias and imprecise results because of the small sample size. Hence, conclusions regarding the efficacy of ethosuximide, valproic acid and lamotrigine derive mostly from the large and high‐quality RCT by <a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a>. Hence, we rated the overall certainty of the evidence for most outcomes to be moderate or high, although we downgraded the certainty of the evidence for outcomes for which data were obtained from small studies judged at unclear or high risk of bias to low or very low certainty. </p> </section> <section id="CD003032-sec-0069"> <h3 class="title" id="CD003032-sec-0069">Potential biases in the review process</h3> <p>We made every effort to identify all RCTs on the use of ethosuximide, valproic acid and lamotrigine for absence seizures through a comprehensive search of the literature, and it is unlikely that we failed to identify large relevant studies. However, despite our efforts, there remains the possibility that we have missed small studies published in the less accessible literature. </p> <p>We also contacted drug companies and experts in the field to obtain information on ongoing trials or unpublished results. </p> <p>Finally, we contacted authors to obtain information on missing data or on completion of study. Unavoidably, some of the authors of this review were familiar with most of the included trials before updating this review. However, data extraction was undertaken blind to the results of the prior version of the review. </p> </section> <section id="CD003032-sec-0070"> <h3 class="title" id="CD003032-sec-0070">Agreements and disagreements with other studies or reviews</h3> <p>The good efficacy profile of ethosuximide for the treatment of absence seizures as shown in <a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a> confirms results of three other smaller studies that compared ethosuximide with valproate (<a href="./references#CD003032-bbs2-0002" title="CallaghanN , O'HareJ , O'DriscollD , O'NeillB , DalyM . Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Developmental Medicine and Clinical Neurology1982;24(6):830-6. ">Callaghan 1982</a>; <a href="./references#CD003032-bbs2-0008" title="SatoS , WhiteBG , PenryJK , DreifussFE , SackellaresJC , KupferbergHJ . Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology1982;32(2):157-63. ">Sato 1982</a>; <a href="./references#CD003032-bbs2-0007" title="MartinovicZ . Comparison of ethosuximide with sodium valproate as monotherapies of absence seizures. In: ParsonageMJ , editors(s). Advances in Epileptology: XIVth Epilepsy International Symposium. New York: Raven Press, 1983:301-5. ">Martinovic 1983</a>); all of these three smaller studies reported a superior efficacy profile for ethosuximide over valproate with regards to seizure freedom (<a href="./references#CD003032-bbs2-0002" title="CallaghanN , O'HareJ , O'DriscollD , O'NeillB , DalyM . Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Developmental Medicine and Clinical Neurology1982;24(6):830-6. ">Callaghan 1982</a>; <a href="./references#CD003032-bbs2-0008" title="SatoS , WhiteBG , PenryJK , DreifussFE , SackellaresJC , KupferbergHJ . Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology1982;32(2):157-63. ">Sato 1982</a>; <a href="./references#CD003032-bbs2-0007" title="MartinovicZ . Comparison of ethosuximide with sodium valproate as monotherapies of absence seizures. In: ParsonageMJ , editors(s). Advances in Epileptology: XIVth Epilepsy International Symposium. New York: Raven Press, 1983:301-5. ">Martinovic 1983</a>), although with wide confidence intervals due to small sample size. However, it is noteworthy to consider that ethosuximide does not suppress tonic‐clonic seizures (<a href="./references#CD003032-bbs2-0027" title="BerkovicSF . Childhood absence epilepsy and juvenile absence epilepsy. In: The Treatment of Epilepsy Principles and Practice. Philadelphia London: Lea &amp; Febiger, 1993:547-51.">Berkovic 1993</a>), and it has even been suggested that it can transform absences into grand mal seizures (<a href="./references#CD003032-bbs2-0031" title="GlauserTA . Succinimides Adverse effects. In: LevyRH , MattsonRH , MeldrumBS , PeruccaE , editors(s). Antiepileptic Drugs. Lippincott Williams &amp; Wilkins, 2002:658-64.">Glauser 2002</a>), although with contrasting data (<a href="./references#CD003032-bbs2-0038" title="SchmittB , Kovacevic-PreradovicT , CritelliH , MolinariL . Is ethosuximide a risk factor for generalised tonic-clonic seizures in absence epilepsy?Neuropediatrics2007;38:83-7.">Schmitt 2007</a>). Hence, ethosuximide should probably be avoided in patients with AS and co‐existing generalised tonic‐clonic seizures. </p> <section id="CD003032-sec-0071"> <h4 class="title">Significance</h4> <p>There are no placebo‐controlled trials for ethosuximide or valproate, and hence no evidence from RCTs to support a specific effect on AS for either of these two drugs. Due to the differing methodologies used in the trials comparing ethosuximide, lamotrigine and valproate, we thought it inappropriate to undertake a meta‐analysis. Hence, guidance for practice from this review are based on a narrative comparison. Further trials with larger size than many of the studies currently included in this review are required. Further research could allow results to be pooled, leading to a quantitative rather than a qualitative summary of results. In summary, ethosuximide, lamotrigine and valproate are commonly used to treat children and adolescents with AS. We now have evidence from a recently conducted, high‐quality, large trial that ethosuximide and valproate have higher efficacy than lamotrigine as initial monotherapy in children and adolescents with AS. This study showed a higher rate of adverse events leading to drug discontinuation and significant negative effects on attentional measures in the valproate group. Consequently, with regards to both efficacy and tolerability, ethosuximide represents the optimal initial empirical monotherapy for children and adolescents with AS. However, the use of ethosuximide should be avoided in patients with AS and generalised tonic‐clonic seizures, as this drug is probably inefficacious on tonic‐clonic seizures. </p> </section> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003032-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/urn:x-wiley:14651858:media:CD003032:CD003032-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram (results refer only to the updated version of the review). The previous versions of the review (Posner 2003; Posner 2005a; Posner 2005b; Brigo 2017; Brigo 2019) included eight studies." data-id="CD003032-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_n/nCD003032-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_t/tCD003032-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram (results refer only to the updated version of the review). The previous versions of the review (<a href="./references#CD003032-bbs2-0044" title="EB Posner, K Mohamed, AG MarsonTG . Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database of Systematic Reviews2003, Issue 3. Art. No: CD003032. [DOI: 10.1002/14651858.CD003032]">Posner 2003</a>; <a href="./references#CD003032-bbs2-0045" title="PosnerEB , MohamedK , MarsonAG . A systematic review of treatment of typical absence seizures in children and adolescents with ethosuximide, sodium valproate or lamotrigine. Seizure2005;14(2):117-22.">Posner 2005a</a>; <a href="./references#CD003032-bbs2-0046" title="PosnerEB , MohamedKK , MarsonAG . Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database of Systematic Reviews2005, Issue 4. Art. No: CD003032. [DOI: 10.1002/14651858.CD003032.pub2]">Posner 2005b</a>; <a href="./references#CD003032-bbs2-0042" title="BrigoF , IgweSC . Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database of Systematic Reviews2017, Issue 2. Art. No: CD003032. [DOI: 10.1002/14651858.CD003032.pub3]">Brigo 2017</a>; <a href="./references#CD003032-bbs2-0043" title="BrigoF , IgweSC , LattanziS . Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents. Cochrane Database of Systematic Reviews2019, Issue 2. Art. No: CD003032. [DOI: 10.1002/14651858.CD003032.pub4]">Brigo 2019</a>) included eight studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/full#CD003032-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_n/nCD003032-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003032-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/urn:x-wiley:14651858:media:CD003032:CD003032-FIG-02" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003032-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_n/nCD003032-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_t/tCD003032-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/full#CD003032-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_n/nCD003032-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003032-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/urn:x-wiley:14651858:media:CD003032:CD003032-FIG-03" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003032-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_n/nCD003032-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_t/tCD003032-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/full#CD003032-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_n/nCD003032-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003032-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/urn:x-wiley:14651858:media:CD003032:CD003032-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ethosuximide versus valproate, Outcome 1: Seizure free" data-id="CD003032-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_n/nCD003032-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_t/tCD003032-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Ethosuximide versus valproate, Outcome 1: Seizure free</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/references#CD003032-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_n/nCD003032-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003032-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/urn:x-wiley:14651858:media:CD003032:CD003032-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ethosuximide versus valproate, Outcome 2: 80% or greater reduction in seizure frequency" data-id="CD003032-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_n/nCD003032-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_t/tCD003032-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Ethosuximide versus valproate, Outcome 2: 80% or greater reduction in seizure frequency </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/references#CD003032-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_n/nCD003032-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003032-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/urn:x-wiley:14651858:media:CD003032:CD003032-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Ethosuximide versus valproate, Outcome 3: 50% or greater reduction in seizure frequency" data-id="CD003032-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_n/nCD003032-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_t/tCD003032-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Ethosuximide versus valproate, Outcome 3: 50% or greater reduction in seizure frequency </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/references#CD003032-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_n/nCD003032-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003032-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/urn:x-wiley:14651858:media:CD003032:CD003032-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Lamotrigine versus valproate, Outcome 1: Seizure free" data-id="CD003032-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_n/nCD003032-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_t/tCD003032-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Lamotrigine versus valproate, Outcome 1: Seizure free</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/references#CD003032-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_n/nCD003032-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003032-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/urn:x-wiley:14651858:media:CD003032:CD003032-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Lamotrigine versus valproate, Outcome 2: Normalisation of the EEG" data-id="CD003032-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_n/nCD003032-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_t/tCD003032-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Lamotrigine versus valproate, Outcome 2: Normalisation of the EEG</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/references#CD003032-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_n/nCD003032-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003032-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/urn:x-wiley:14651858:media:CD003032:CD003032-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Ethosuximide versus lamotrigine, Outcome 1: Seizure free at 12 months" data-id="CD003032-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_n/nCD003032-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_t/tCD003032-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Ethosuximide versus lamotrigine, Outcome 1: Seizure free at 12 months</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/references#CD003032-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/media/CDSR/CD003032/image_n/nCD003032-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003032-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Ethosuximide compared to valproate for absence seizures in children and adolescents</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Ethosuximide compared to valproate for absence seizures in children and adolescents</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> absence seizures in children and adolescents<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> ethosuximide<br/><b>Comparison:</b> valproate </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with valproate</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ethosuximide</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Seizure freedom at 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>365<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>None of the included trials found a difference for this outcome.</p> <p>Length of follow‐up in included studies: from 6 weeks to 4 years.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>80% or greater reduction in seizure frequency</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.70<br/>(0.19 to 2.59) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>29<br/>(1 RCT)<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No difference was found, but the confidence interval is wide and equivalence cannot be inferred. </p> <p>Length of follow‐up: 6 weeks.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>286 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>200 per 1,000<br/>(54 to 740) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>50% or greater reduction in seizure frequency</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>49<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW <sup>4,5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>No difference was found, but the confidence interval is wide and equivalence cannot be inferred. </p> <p>Length of follow‐up in included studies: from 1 to 4 years.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normalisation of the EEG ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Adverse effects (<a href="./full#CD003032-tbl-0002">Table 1</a>; <a href="./full#CD003032-tbl-0003">Table 2</a>) </p> <p>Ethosuximide treatment was mostly associated with nausea, vomiting, and behavioural/psychiatric changes. </p> <p>The most common adverse effects of treatment with valproate were fatigue, nausea, vomiting, increased appetite with weight gain, behavioural/psychiatric changes (decreased concentration, personality change, hyperactivity, attention problems, hostility), and thrombocytopenia </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Most information is from studies at low or unclear risk of bias; plausible bias is likely to seriously alter the results. </p> <p><sup>2</sup> Information is from a study with unclear and high risk of bias; plausible bias is likely to seriously alter the results. </p> <p><sup>3</sup> Small number of patients included in this study (29) (see also footnote below). </p> <p><sup>4</sup> Information is from two small studies with unclear or high risk of bias; plausible bias is likely to seriously alter the results. </p> <p><sup>5</sup> Information is from two studies with small number of patients included. </p> <p><sup>a</sup>In this study, one patient in the ethosuximide group was subsequently treated with valproate, but failed to respond to either single drug and did not improve when both drugs were used in combination. The outcomes of this patient on combined treatment were therefore counted twice ("no remission"), since the patient received both drugs. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Ethosuximide compared to valproate for absence seizures in children and adolescents</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/full#CD003032-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003032-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adverse effects on valproate: number of participants experiencing each event</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Event</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0002" title="CallaghanN , O'HareJ , O'DriscollD , O'NeillB , DalyM . Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Developmental Medicine and Clinical Neurology1982;24(6):830-6. "><b>Callaghan 1982</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0008" title="SatoS , WhiteBG , PenryJK , DreifussFE , SackellaresJC , KupferbergHJ . Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology1982;32(2):157-63. "><b>Sato 1982</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0007" title="MartinovicZ . Comparison of ethosuximide with sodium valproate as monotherapies of absence seizures. In: ParsonageMJ , editors(s). Advances in Epileptology: XIVth Epilepsy International Symposium. New York: Raven Press, 1983:301-5. "><b>Martinovic 1983</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0003" title="CoppolaG , AuricchioG , FedericoR , CarotenutoM , PascottoA . Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia2004;45(9):1049-53. CoppolaG , LervolinoG , MastrosimoneM , La TorreG , RuiuF , PascottoA . Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development2004;26(6):373-6. "><b>Coppola 2004</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. "><b>Huang 2009</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. "><b>Glauser 2013a</b> </a> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Acute pancreatitis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Obesity/Weight gain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Decreased platelet numbers</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperactivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Attention problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hostility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Concentration decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Personality change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleep problem</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Slow process speed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Memory problem</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Apathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elevated liver function tests</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Elevated LDH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*Nausea, vomiting, or both<br/>LDH: lactate dehydrogenase </p> <p>Numbers of individuals within each study undertaking valproate: 14 (<a href="./references#CD003032-bbs2-0002" title="CallaghanN , O'HareJ , O'DriscollD , O'NeillB , DalyM . Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Developmental Medicine and Clinical Neurology1982;24(6):830-6. ">Callaghan 1982</a>), 22 (<a href="./references#CD003032-bbs2-0008" title="SatoS , WhiteBG , PenryJK , DreifussFE , SackellaresJC , KupferbergHJ . Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology1982;32(2):157-63. ">Sato 1982</a>), 10 (<a href="./references#CD003032-bbs2-0007" title="MartinovicZ . Comparison of ethosuximide with sodium valproate as monotherapies of absence seizures. In: ParsonageMJ , editors(s). Advances in Epileptology: XIVth Epilepsy International Symposium. New York: Raven Press, 1983:301-5. ">Martinovic 1983</a>), 19 (<a href="./references#CD003032-bbs2-0003" title="CoppolaG , AuricchioG , FedericoR , CarotenutoM , PascottoA . Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia2004;45(9):1049-53. CoppolaG , LervolinoG , MastrosimoneM , La TorreG , RuiuF , PascottoA . Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development2004;26(6):373-6. ">Coppola 2004</a>), 23 (<a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. ">Huang 2009</a>), 146 (<a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Adverse effects on valproate: number of participants experiencing each event</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/full#CD003032-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003032-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse effects on ethosuximide: number of participants experiencing each event</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Event</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0002" title="CallaghanN , O'HareJ , O'DriscollD , O'NeillB , DalyM . Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Developmental Medicine and Clinical Neurology1982;24(6):830-6. "><b>Callaghan 1982</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0008" title="SatoS , WhiteBG , PenryJK , DreifussFE , SackellaresJC , KupferbergHJ . Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology1982;32(2):157-63. "><b>Sato 1982</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0007" title="MartinovicZ . Comparison of ethosuximide with sodium valproate as monotherapies of absence seizures. In: ParsonageMJ , editors(s). Advances in Epileptology: XIVth Epilepsy International Symposium. New York: Raven Press, 1983:301-5. "><b>Martinovic 1983</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. "><b>Glauser 2013a</b> </a> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Drowsiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Tiredness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Leukopenia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hiccups</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Moodiness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperactivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Attention problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hostility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Concentration decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Personality change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleep problem</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Slow process speed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Memory problem</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Apathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>* Nausea, vomiting, or both</p> <p>Numbers of individuals within each study undertaking ethosuximide: 14 (<a href="./references#CD003032-bbs2-0002" title="CallaghanN , O'HareJ , O'DriscollD , O'NeillB , DalyM . Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal). Developmental Medicine and Clinical Neurology1982;24(6):830-6. ">Callaghan 1982</a>), 23 (<a href="./references#CD003032-bbs2-0008" title="SatoS , WhiteBG , PenryJK , DreifussFE , SackellaresJC , KupferbergHJ . Valproic acid versus ethosuximide in the treatment of absence seizures. Neurology1982;32(2):157-63. ">Sato 1982</a>), 10 (<a href="./references#CD003032-bbs2-0007" title="MartinovicZ . Comparison of ethosuximide with sodium valproate as monotherapies of absence seizures. In: ParsonageMJ , editors(s). Advances in Epileptology: XIVth Epilepsy International Symposium. New York: Raven Press, 1983:301-5. ">Martinovic 1983</a>), 154 (<a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Adverse effects on ethosuximide: number of participants experiencing each event</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/full#CD003032-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003032-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Lamotrigine compared to valproate for absence seizures in children and adolescents</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Lamotrigine compared to valproate for absence seizures in children and adolescents</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> absence seizures in children and adolescents<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> lamotrigine<br/><b>Comparison:</b> valproate </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with valproate</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with lamotrigine</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Seizure freedom at 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>405<br/>(4 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Higher proportion seizure free at 1 month in patients receiving valproate compared to those receiving lamotrigine (2 studies). </p> <p>No difference between valproate and lamotrigine for seizure freedom at 3 and 6 months (3 and 4 studies, respectively). </p> <p>Length of follow‐up in included studies: 12 months.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>see comment</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80% or greater reduction in seizure frequency ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50% or greater reduction in seizure frequency ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Normalisation of the EEG</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.39<br/>(1.14 to 5.04) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>45<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>VERY LOW <sup>2,3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Length of follow‐up: 12 months.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>273 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>652 per 1,000<br/>(311 to 1,000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Adverse effects (<a href="./full#CD003032-tbl-0002">Table 1</a>; <a href="./full#CD003032-tbl-0005">Table 3</a>) </p> <p>The most common adverse effects of treatment with lamotrigine were fatigue, and behavioural/psychiatric changes. </p> <p>The most common adverse effects of treatment with valproate were fatigue, nausea, vomiting, increased appetite with weight gain, behavioural/psychiatric changes (decreased concentration, personality change, hyperactivity, attention problems, hostility), and thrombocytopenia </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Most information comes from studies at low or unclear risk of bias; plausible bias is likely to seriously alter the results.<br/><sup>2</sup> Information comes from a small study at unclear and high risk of bias.<br/><sup>3</sup> Information comes from a single study conducted in a small number of patients. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Lamotrigine compared to valproate for absence seizures in children and adolescents</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/full#CD003032-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD003032-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse effects on lamotrigine: number of participants experiencing each event</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Event</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0004" title="FrankLM , EnlowT , HolmesGL , ManascoP , ConcannonS , ChenC , et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia1999;40(7):973-9. FrankLM , MessenheimerJA , VuongA , WarnockCR . Childhood absence seizures: onset of treatment efficacy with lamotrigine [Abstract: Proceedings of the Annual Meeting of the American Epilepsy Society, New Orleans, Louisiana. December 3-7 2004. Abstract no 2.282]. Epilepsia2004;45(Suppl 7):320. "><b>Frank 1999</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0003" title="CoppolaG , AuricchioG , FedericoR , CarotenutoM , PascottoA . Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia2004;45(9):1049-53. CoppolaG , LervolinoG , MastrosimoneM , La TorreG , RuiuF , PascottoA . Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development2004;26(6):373-6. "><b>Coppola 2004</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. "><b>Huang 2009</b> </a> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. "><b>Glauser 2013a</b> </a> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Abdominal pain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Headache</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nausea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Vomiting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2*</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Poor appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Increased appetite</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diarrhoea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dizziness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperkinesia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hyperactivity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Attention problems</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Hostility</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Concentration decreased</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Personality change</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sleep problem</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Depression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Slow process speed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Memory problem</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Apathy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fatigue</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Rash</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nervousness</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diplopia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>*Nausea, vomiting, or both</p> <p>Numbers of individuals within each study undertaking lamotrigine: 15 (<a href="./references#CD003032-bbs2-0004" title="FrankLM , EnlowT , HolmesGL , ManascoP , ConcannonS , ChenC , et al. Lamictal (lamotrigine) monotherapy for typical absence seizures in children. Epilepsia1999;40(7):973-9. FrankLM , MessenheimerJA , VuongA , WarnockCR . Childhood absence seizures: onset of treatment efficacy with lamotrigine [Abstract: Proceedings of the Annual Meeting of the American Epilepsy Society, New Orleans, Louisiana. December 3-7 2004. Abstract no 2.282]. Epilepsia2004;45(Suppl 7):320. ">Frank 1999</a>), 19 (<a href="./references#CD003032-bbs2-0003" title="CoppolaG , AuricchioG , FedericoR , CarotenutoM , PascottoA . Lamotrigine versus valproic acid as first-line monotherapy in newly diagnosed typical absence seizures: an open-label, randomized, parallel-group study. Epilepsia2004;45(9):1049-53. CoppolaG , LervolinoG , MastrosimoneM , La TorreG , RuiuF , PascottoA . Melatonin in wake-sleep disorders in children, adolescents and young adults with mental retardation with or without epilepsy: a double-blind, cross-over, placebo-controlled trial. Brain and Development2004;26(6):373-6. ">Coppola 2004</a>), 24 (<a href="./references#CD003032-bbs2-0006" title="HuangTS , ZhuJL , LiB , HuY , ChenL , LiaoJX . Valproic acid versus lamotrigine as a monotherapy for absence epilepsy in children. Zhongguo Dangdai Erke Zazhi2009;11(8):653-5. ">Huang 2009</a>), 146 (<a href="./references#CD003032-bbs2-0005" title="GlauserTA , CnaanA , ShinnarS , HirtzDG , DlugosD , MasurD , et al, Childhood Absence Epilepsy Study Team. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months. Epilepsia2013;54(1):141-55. ">Glauser 2013a</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Adverse effects on lamotrigine: number of participants experiencing each event</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/full#CD003032-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003032-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Ethosuximide compared to lamotrigine for absence seizures in children and adolescents</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Ethosuximide compared to lamotrigine for absence seizures in children and adolescents</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> absence seizures in children and adolescents<br/><b>Setting:</b> outpatients<br/><b>Intervention:</b> ethosuximide<br/><b>Comparison:</b> lamotrigine </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Outcomes</b> </p> </th> <th align="left" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with lamotrigine</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Risk with ethosuximide</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Seizure freedom at 12 months</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.47<br/>(0.33 to 0.67) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>300<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊕<br/>HIGH </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Length of follow‐up: 12 months.</p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>455 per 1,000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>214 per 1,000<br/>(150 to 305) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80% or greater reduction in seizure frequency ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50% or greater reduction in seizure frequency ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Normalisation of the EEG ‐ not reported</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>Adverse effects (<a href="./full#CD003032-tbl-0003">Table 2</a>; <a href="./full#CD003032-tbl-0005">Table 3</a>) </p> <p>Ethosuximide treatment was mostly associated with nausea, vomiting, and behavioural/psychiatric changes. </p> <p>The most common adverse effects of treatment with lamotrigine were fatigue, and behavioural/psychiatric changes. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Ethosuximide compared to lamotrigine for absence seizures in children and adolescents</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/full#CD003032-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003032-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ethosuximide versus valproate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Seizure free <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1.1 Drug naive</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 80% or greater reduction in seizure frequency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Previously treated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 50% or greater reduction in seizure frequency <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Ethosuximide versus valproate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/references#CD003032-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003032-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Lamotrigine versus valproate</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Seizure free <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Seizure free at 1 month</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Seizure free at 3 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.3 Seizure freedom at 6 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.4 Seizure free at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Normalisation of the EEG <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Lamotrigine versus valproate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/references#CD003032-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003032-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Ethosuximide versus lamotrigine</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Seizure free at 12 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Ethosuximide versus lamotrigine</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003032.pub5/references#CD003032-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003032.pub5&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003032-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003032-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003032-note-0011">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD003032-note-0009">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD003032-note-0012">Polski</a> </li> <li class="section-language"> <a class="" href="th#CD003032-note-0008">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD003032-note-0007">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003032\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003032\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003032\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003032\x2epub5"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003032\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003032\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003032\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003032\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003032\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003032\x2epub5"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003032\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003032\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003032\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003032\x2epub5"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003032\x2epub5\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003032\x2epub5\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003032\x2epub5\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003032\x2epub5"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=kKvAiZoF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003032.pub5&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003032.pub5';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003032.pub5/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003032.pub5/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003032.pub5%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717582336"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003032.pub5/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717582340"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003032.pub5/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dbb739ae99371',t:'MTc0MDcxNzU4Mi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 